



## **Keystone 65 Preferred Rx HMO, Keystone 65 Select Rx HMO, and Personal Choice 65<sup>SM</sup> Rx PPO**

### **2025 Utilization Management Criteria: Prior Authorization**

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION  
ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN**

This document was updated on **10/01/2024**. For more recent information or other questions, please contact our Member Help Team: Keystone 65 Rx at **1-800-645-3965**, Personal Choice 65 Rx at **1-888-718-3333**, or, for TTY/TDD users, **711**, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from April 1 through September 30, your call may be sent to voicemail. Or, visit **[www.ibxmedicare.com](http://www.ibxmedicare.com)** to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to “we,” “us,” or “our,” it means Independence Blue Cross. When it refers to “plan” or “our plan,” it means Keystone 65 Rx and Personal Choice 65 Rx.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2026, and from time to time during the year.

Independence Blue Cross offers PPO, HMO-POS, and HMO Medicare Advantage plans with a Medicare contract. Enrollment in Independence Blue Cross PPO, HMO-POS, and HMO Medicare Advantage plans depends on contract renewal.

Independence Blue Cross offers products through its subsidiaries Independence Assurance Company, Independence Hospital Indemnity Plan, Keystone Health Plan East, and QCC Insurance Company — independent licensees of the Blue Cross and Blue Shield Association.

## There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this “utilization management.” These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don’t get approval, our plan may not cover the drug. Drugs that require prior authorization are listed in this document.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require step therapy are listed in *2025 Utilization Management Criteria: Step Therapy*.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have quantity limits are listed in the *Keystone 65 Preferred Rx HMO, Keystone 65 Select Rx HMO, and Personal Choice 65 Rx PPO (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting [www.ibxmedicare.com](http://www.ibxmedicare.com).

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

## How to use this document

This document, along with *2025 Utilization Management Criteria: Step Therapy*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note “PA” in the “Requirements” column of the *Keystone 65 Preferred Rx HMO, Keystone 65 Select Rx HMO, and Personal Choice 65 Rx PPO Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 179. The restriction information includes:

- **Prior Authorization**
  - Covered uses
  - Exclusion criteria
  - Required medical information
  - Age restrictions
  - Prescriber restrictions
  - Coverage duration
  - Other criteria

Be sure to read all the information listed for your affected drug. If you have any questions or need assistance with the information contained in this document, please call our Member Help Team: Keystone 65 Rx at **1-800-645-3965** or Personal Choice 65 Rx at **1-888-718-3333** or, for TTY/TDD users, **711**.

# ABUSE DETERRENT OPIOID 2025

## Products Affected

- *hydrocodone bitartrate er oral capsule extended release 12 hour 10 mg, 15 mg*
- XTAMPZA ER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of one of the following: (1) Prior use of TWO generic opioids OR (2) BOTH of the following: (a) there is a history of or a potential for drug abuse among the individual or a member of the individual's household AND (b) documentation of current patient-prescriber opioid treatment agreement
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACTEMRA SQ 2025

## Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PJIA, SJIA, RA, GCA, SSc-ILD): Concurrent therapy with other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists.
<b>Required Medical Information</b>	Part D is medically necessary when there is documentation of the following: Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of PJIA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adulimumab-ADB), (b) etanercept (Enbrel), (c) Xeljanz, (d) Orencia, OR documentation demonstrating that a trial may be inappropriate. Systemic Juvenile Idiopathic Arthritis (SJIA): (1) Diagnosis of SJIA. (2) Inadequate response or inability to tolerate ONE of the following: (a) Non-steroidal anti-inflammatory drug (NSAID), (b) Systemic glucocorticoid, (c) Methotrexate. Moderate to severe rheumatoid arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e., Humira, Adulimumab-ADB), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia, OR documentation demonstrating that a trial may be inappropriate. Giant Cell Arteritis (GCA): (1) Diagnosis of GCA. (2) Documentation of inadequate response/inability to tolerate oral corticosteroids. Systemic Sclerosis (SSc-ILD) (1): Diagnosis of SSc-ILD (2) Documentation of inadequate response/inability to tolerate a 3-month trial of ONE of the following:(a) mycophenolate mofetil, (b) cyclophosphamide, OR (c) azathioprine (3) Diagnosis of SSc-ILD confirmed by a high-resolution CT scan or biopsy
<b>Age Restrictions</b>	(PJIA, SJIA): Member is 2 years of age or older (RA, GCA, SSc-ILD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PJIA, SJIA, RA, GCA): Prescribed by or in consultation with a Rheumatologist (SSc-ILD) -Prescribed by or in consultation with a rheumatologist or pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.

PA Criteria	Criteria Details
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACTHAR HP 2025

## Products Affected

- ACTHAR
- CORTROPHIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(All Indications): Scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins or porcine origin, or where congenital infections are suspected in infants. OR Administration of live or live attenuated vaccines in members receiving immunosuppressive doses of H.P. Acthar Gel.
<b>Required Medical Information</b>	Part D is medically necessary when ONE of the following is present: (1) Infantile Spasms (IS): (A) Diagnosis of IS. (B) Dosing for infantile spasms (West Syndrome) is in accordance with the United States Food and Drug Administration (FDA) approved labeling: not to exceed 150U/m2 daily (2) Acute Exacerbation of Multiple Sclerosis (AEMS): (A) Diagnosis of an AEMS, (B) Currently receiving maintenance treatment for MS (e.g. Avonex, Betaseron, Copaxone, Tecfidera, etc.), (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone) (D) Member is new to therapy with corticotropin OR member's multiple sclerosis exacerbations have been treated in the past with corticotropin AND member has benefitted from treatment with corticotropin for acute exacerbations of multiple sclerosis AND medication is being used to treat a new exacerbation of multiple sclerosis. (3) Acute Exacerbation of Psoriatic Arthritis (AEPsA): (A) Diagnosis of an AEPsA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (4) Acute Exacerbation of Rheumatoid Arthritis (AERA): (A) Diagnosis of an AERA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (5) Acute Exacerbation of Juvenile Rheumatoid Arthritis (AEJRA): (A) Diagnosis of an AEJRA, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (6) Acute Exacerbation of Ankylosing Spondylitis (AEAS): (A) Diagnosis of an AEAS, (B) Currently receiving a DMARD, (C) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone).

PA Criteria	Criteria Details
<b>Age Restrictions</b>	(IS): Member is younger than 2 years of age. (MS): Member is 18 years of age and older. (All Other Indications): Member is 2 years of age and older
<b>Prescriber Restrictions</b>	(IS): Prescribed by or in consultation with an neurologist or neonatologist. (All Other Indications): Prescribed by or in consultation with a neurologist, rheumatologist, nephrologist, pulmonologist, ophthalmologist, dermatologist, allergist, immunologist.
<b>Coverage Duration</b>	(IS): 1 year (All Other Indications): 1 month
<b>Other Criteria</b>	Subject to Part B vs Part D review. (7) Nephrotic Syndrome (NS): (A) Diagnosis of NS, (B) Proteinuria greater than 3.5g/ 24 hours, (C) serum albumin less than 3 mg/dL, (D) Peripheral edema. (E) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (F) Member does not have uremia of the idiopathic type (8) Systemic Lupus Erythematosus (SLE): (A) Diagnosis of SLE (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (9) Systemic Dermatomyositis (SDM): (A) Diagnosis of SDM (polymyositis), (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (10) Severe Erythema Multiforme (SEM): (A) Diagnosis of SEM, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (11) Stevens-Johnson Syndrome (SJS): (A) Diagnosis of SJS, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (12) Serum Sickness (SS): (A) Diagnosis of SS, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (13) Inflammatory Ophthalmic Disease (IOD): (A) Diagnosis of IOD such as Keratitis, Iritis, Iridocyclitis, Diffuse posterior uveitis and choroiditis, Optic neuritis, Chorioretinitis, Anterior segment inflammation, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (14) Symptomatic Sarcoidosis (SSD): (A) Diagnosis of SSD, (B) Inadequate response or inability to tolerate two systemic steroids (e.g. prednisone, methylprednisolone). (15) Edematous state: To induce a diuresis or a remission of proteinuria due to lupus erythematosus (ALL INDICATIONS): Dosing is in accordance with the United States Food and Drug Administration (FDA) approved labeling
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ACUTE HAE AGENTS 2025 - Pending CMS Review

## Products Affected

- FIRAZYR SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when the following inclusion criteria is met: Hereditary Angioedema (HAE): (1) Used for the treatment of acute abdominal, facial or laryngeal attacks of HAE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(HAE): Prescribed by or in consultation with an allergist, pulmonologist, or immunologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ACUTE SEIZURE ACTIVITY AGENTS 2025

---

## Products Affected

- LIBERVANT
- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE
- VALTOCO 20 MG DOSE
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescriber is a neurologist/epilepsy specialist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADALIMUMAB PREFERRED PRODUCTS 2025

## Products Affected

- *adalimumab-adbm (2 pen)*
- *adalimumab-adbm (2 syringe)*
- *adalimumab-adbm(cd/uc/hs strt)*
- *adalimumab-adbm(ps/uv starter)*
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, AS, JIA, PsA, PsO, CD, UC, HS, UV): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1)Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate. Juvenile Idiopathic Arthritis (JIA): (1) Diagnosis of moderate to severe JIA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, leflunomide, sulfasalazine. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO.
<b>Age Restrictions</b>	Member is within the age group listed in the FDA labeling for the indication
<b>Prescriber Restrictions</b>	(RA, JIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (PsO, HS): Prescribed by or in consultation with a dermatologist. (CD, UC): Prescribed by or in consultation with a gastroenterologist. (UV): Prescribed by or in consultation with a rheumatologist or ophthalmologist.
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, methotrexate, azathioprine or 6-mercaptopurine). Ulcerative Colitis (UC): (1) Diagnosis of UC. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, aminosalicylate, azathioprine or 6-mercaptopurine). Hidradenitis Suppurativa (HS): (1) Diagnosis of HS. Uveitis (UV): (1) Diagnosis of non-infectious intermediate, posterior, or pan- uveitis. (2) Inadequate response or inability to tolerate corticosteroids and at least one immunosuppressive drug (e.g. azathioprine, cyclosporine, methotrexate, mycophenolate).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADBRY 2025

---

## Products Affected

- ADBRY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Diagnosis of moderate to severe AD (2) inadequate response or inability to tolerate TWO of the following: (a) one topical steroid (medium potency or higher) (b) topical tacrolimus (c) Eucrisa (crisaborole) ointment (d) Pimecrolimus cream
<b>Age Restrictions</b>	(AD): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ADEMPAS 2025

## Products Affected

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PAH, CTEPH) (Initial, Reauth): Concurrent use of phosphodiesterase inhibitors, nitrates or nitric oxide donors, pregnancy, concurrent use with other soluble guanylate cyclase stimulators (e.g. Verquvo)
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II - IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (initial): (1) Diagnosis of persistent/recurrent CTPH (WHO Group 4) after surgical treatment or inoperable CTEPH.
<b>Age Restrictions</b>	(PAH, CTEPH) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PAH, CTEPH) (initial, Reauth): Prescribed by or in consultation with a pulmonologist or cardiologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth):12 months
<b>Other Criteria</b>	(PAH, CPTEH) (Reauth): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AIMOVIG 2025

## Products Affected

- AIMOVIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Documentation of concomitant use with another injectable CGRP inhibitor.
<b>Required Medical Information</b>	Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4-week trial of or contraindication to TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine, (f) candesartan OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate a 4 week trial of or contraindication to TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine (vi) candesartan.
<b>Age Restrictions</b>	(Migraines)(Initial, Reauth): Member 18 years of age or older
<b>Prescriber Restrictions</b>	(Migraines)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist
<b>Coverage Duration</b>	(Migraines)(Initial): 6 months (Migraines)(Reauth): 12 months
<b>Other Criteria</b>	(Migraines)(REAUTH): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AMBRISENTAN 2025

## Products Affected

- *ambrisentan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AMPYRA 2025

## Products Affected

- AMPYRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	MS (Initial): Member has history of seizure or moderate to severe renal impairment (CrCL less than or equal to 50 mL/min)
<b>Required Medical Information</b>	Multiple Sclerosis (MS) (Initial): (1) Diagnosis of multiple sclerosis. (2) Confirmation that member has difficulty walking. (3) Inadequate response or inability to tolerate dalfampridine (applies to brand Ampyra).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(MS) (Initial and Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial, Reauth): Remainder of contract year
<b>Other Criteria</b>	(MS) (Reauth): Documentation of positive clinical response as evidenced by improvement in walking speed
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ANTICHOLINERGIC HRM 2025

## Products Affected

- *chlordiazepoxide-clidinium*
- *promethazine hcl oral tablet 12.5 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years Poly-ACH DUR- 1 year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable. Subject to additional clinical review for Poly-ACH cDUR related use - if applicable. (1) The drug is being prescribed for a medically accepted indication (2) The prescriber acknowledges anticholinergic risks (e.g., confusion, dry mouth, blurry vision, constipation, urinary retention) (3) The prescriber will consider lowering the dose or discontinuing medication(s) that are no longer clinically warranted for the member
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ARIKAYCE 2025

## Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(MAC): (1) Diagnosis of Mycobacterium avium complex (MAC) lung disease (2) Medication is being used as part of a combination antibacterial drug regimen (3) Used in patients who have not achieved at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy
<b>Age Restrictions</b>	Member is 18 years of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a pulmonologist or an infectious disease specialist
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ARMODAFINIL 2025

## Products Affected

- *armodafinil*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>NARCOLEPSY: (1) Diagnosis of Narcolepsy confirmed by a sleep study (unless prescriber provides justification that a sleep study is not feasible).</p> <p>OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). (2) Both of the following (a): 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study is not feasible) AND (b) One of the following symptoms: Unintentional sleep episodes during wakefulness, or daytime sleepiness, or unrefreshing sleep, or fatigue, or insomnia, or waking up breath holding, gasping, or choking, or loud snoring, or breathing interruptions during sleep.</p> <p>SHIFT WORK SLEEP DISORDER (SWSD): (1) One of the following: (a) Symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR (b) A sleep study demonstrating loss of a normal sleep-wake pattern (i.e., disturbed chronobiologic rhythmicity). (2) Documentation that the member has no other medical or mental disorder accounting for the symptoms.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy, SWSD, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUSTEDO 2025

## Products Affected

- AUSTEDO
- AUSTEDO XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Chorea-Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD)(Initial, Continuation): Prescribed by or in consultation with a neurologist or a psychiatrist.
<b>Coverage Duration</b>	(TD)(Initial): 3 months. (TD)(Reauth): Indefinite. (CHD): Indefinite.
<b>Other Criteria</b>	(TD)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# AUVELITY 2025

---

## Products Affected

- AUVELITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Major Depressive Disorder (MDD): (1) Diagnosis of major depressive disorder (MDD) (2) Inadequate response or inability to tolerate two formulary antidepressants indicated for MDD (e.g. bupropion, venlafaxine extended-release tablet or capsule, sertraline tablet, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(MDD): Approve if for continuation of therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BENLYSTA SC 2025

## Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when the following are met: Systemic Lupus Erythematosus (SLE): (1) Diagnosis of active, autoantibody-positive SLE. (2) Member is receiving concurrent treatment with at least ONE of the following: steroids, antimalarials, immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDS). Lupus Nephritis (LN): (1) Diagnosis of active lupus nephritis confirmed by kidney biopsy. (2) Member is receiving concurrent standard therapy (e.g. corticosteroids, immunosuppressants, azathioprine).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SLE): Prescribed by or in consultation with a rheumatologist. (LN): Prescribed by or in consultation with a nephrologist or rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BESREMI 2025

## Products Affected

- BESREMI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# BRAND ANTIPSYCHOTICS ACH 2025 - Pending CMS Review

## Products Affected

- LYBALVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Trial of two generic formulary antipsychotics. Applies to new starts.
<b>Age Restrictions</b>	POLY-ACH DUR: Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	PA: Indefinite Poly-ACH DUR: 1 year
<b>Other Criteria</b>	Subject to additional clinical review for Poly-ACH cDUR related use - if applicable. (1) The drug is being prescribed for a medically accepted indication (2) The prescriber acknowledges anticholinergic risks (e.g., confusion, dry mouth, blurry vision, constipation, urinary retention) (3) The prescriber will consider lowering the dose or discontinuing medication(s) that are no longer clinically warranted for the member
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# CAPLYTA 2025

## Products Affected

- CAPLYTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Schizophrenia: (1) Diagnosis of schizophrenia (2) Inadequate response or inability to tolerate two generic antipsychotic products (e.g. aripiprazole, olanzapine, quetiapine, paliperidone). Bipolar Depression (BD): (1) Diagnosis of bipolar depression (2) Medication will be used as monotherapy or as adjunctive therapy with lithium or valproate (3) Inadequate response or inability to tolerate two medications indicated for bipolar depression (e.g. fluoxetine, Latuda, quetiapine, olanzapine)
<b>Age Restrictions</b>	(Schizophrenia, BP): member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Schizophrenia, BP): Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CAYSTON 2025

## Products Affected

- CAYSTON

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of CF. (2) Evidence of Pseudomonas Aeruginosa in the lungs. (3) Susceptibility results indicating that the Pseudomonas aeruginosa is sensitive to aztreonam. (4) FEV1 between 25% and 75% of predicted
<b>Age Restrictions</b>	(CF): Member is 7 years of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with a pulmonologist OR infectious disease specialist or Specialist affiliated with a CF care center.
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Reauth: (1) Evidence of Pseudomonas aeruginosa in the lungs (2) Documentation of positive clinical response to therapy (e.g. improvement in lung function demonstrated by improved FEV1)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CHOLBAM 2025

## Products Affected

- CHOLBAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(BASD, PD)(Initial, Reauth): Extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects or peroxisomal disorders including Zellweger spectrum disorders
<b>Required Medical Information</b>	Bile Acid Synthesis Disorder (BASD) (initial): (1) Diagnosis of bile acid synthesis disorder due to a single enzyme defect. Peroxisomal disorder (PD) (initial): (1) Diagnosis of peroxisomal disorder. (2) Used as adjunctive treatment. (3) Member exhibits manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(BASD, PD): Hepatologist, Gastroenterologist, Medical geneticist, other specialist that treats inborn errors of metabolism
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): Indefinite
<b>Other Criteria</b>	(BASD,PD) (Reauth): Documentation of improved liver function tests from the start of treatment.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CIALIS 2025

---

## Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(BPH): Concurrent use of nitrates.
<b>Required Medical Information</b>	Benign prostatic hyperplasia (BPH): (1) Diagnosis of BPH. (2) Inadequate response or inability to tolerate an alpha blocker (e.g. tamsulosin, terazosin) or a 5-alpha reductase inhibitor (e.g. dutasteride, finasteride).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CIBINQO 2025

## Products Affected

- CIBINQO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AD): Concurrent use with any other biologic immunomodulator, Janus Kinase (JAK) inhibitors, or other immunosuppressants (e.g. azathioprine, cyclosporine)
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Diagnosis of refractory, moderate to severe AD (2) Inadequate response or inability to tolerate one systemic drug product, including biologics (e.g. Dupixent, methylprednisolone, prednisone) or member has a contraindication, intolerance, or treatment is inadvisable with both of the following FDA-approved atopic dermatitis therapies: Adbry (tralokinumab-ldrm) AND Dupixent (dupilumab) or documentation that a trial may be inappropriate.
<b>Age Restrictions</b>	(AD): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CIMZIA 2025

## Products Affected

- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AS, PsA, PsO, RA, CD, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate two of the following: (a) secukinumab (Cosentyx), (b) Adalimumab (i.e., Humira, Adulimumab-ADB), (c) etanercept (Enbrel), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) upadacitinib (Rinvoq), or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adulimumab-ADB), (b) Enbrel, (c) Xeljanz/Xeljanz XR (d) Rinvoq, (e) Skyrizi, (f) Cosentyx, (g) Stelara, (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adulimumab-ADB), (b) Enbrel, (c) Skyrizi (d) Cosentyx, (e) Stelara, (f) Otezla OR documentation demonstrating that a trial may be inappropriate. Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adulimumab-ADB), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Crohn's Disease (CD): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e., Humira, Adulimumab-ADB), (b) ustekinumab (Stelara), (c) risankizumab (Skyrizi), (d) upadacitinib (Rinvoq) or documentation demonstrating that a trial may be inappropriate. Non-radiographic axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA. (2) Inadequate response or inability to tolerate one of the following: (a) two NSAIDs (b) Cosentyx (c) Rinvoq or (d) documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(AS, PsA, PsO, RA, CD, nr-axSpA): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CD): Prescribed by or in consultation with a gastroenterologist. (RA, AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist. (PsA, PsO): prescribed by or in consultation with a dermatologist or rheumatologist.

PA Criteria	Criteria Details
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# COMBINATION NSAID PRODUCTS 2025

## Products Affected

- *naproxen-esomeprazole mg oral tablet delayed release 500-20 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(All Indications)(Initial): An inadequate response or inability to tolerate a two-week trial of BOTH of the following: (1) Concurrent administration of each of the components of the requested product, and (2) At least ONE generic alternative (when available) of each of the individual components of the requested product.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(All Indication) (Initial, Reauth): 1 year
<b>Other Criteria</b>	(All Indications)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# CORLANOR 2025 - Pending CMS Review

## Products Affected

- CORLANOR ORAL SOLUTION
- *ivabradine hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Chronic Heart Failure (CHF): (1)Diagnosis of chronic heart failure. (2) stable, symptomatic chronic heart failure (3) left ventricular ejection fraction less than or equal to 35% and (4) sinus rhythm with resting heart rate greater than or equal to 70 beats per minute. (5) Member is clinically stable for at least 4 weeks on an optimized regimen which includes 2 of the following therapies: (a) maximally tolerated doses of beta blockers or inability to tolerate beta blockers, (b) ACE inhibitors or ARBs or inability to tolerate ACE inhibitor or ARB. (c) maximally tolerated doses of Sodium-glucose co-transporter 2 (SGLT2) inhibitor [e.g. Jardiance (empagliflozin), Farxiga (dapagliflozin), Xigduo XR (dapagliflozin and metformin)] (d) maximally tolerated doses of mineralocorticoid receptor antagonist (MRA) [e.g. eplerenone, spironolactone]</p> <p>Chronic Heart Failure due to Dilated Cardiomyopathy in pediatric patients ages 6 months and older (CHF-DC): (1) Diagnosis of chronic heart failure due to dilated cardiomyopathy (2) Member is in sinus rhythm with an elevated heart rate.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CHF, CHF-DC): Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# COSENTYX SQ 2025 - Pending CMS Review

## Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsA, PsO, AS, nr-axSpA, ERA, HS): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least ONE DMARD Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe plaque psoriasis. Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA, (2) Inadequate response or inability to tolerate two NSAIDs. Active Enthesitis-related Arthritis (ERA): (1) Diagnosis of active enthesitis-related arthritis (ERA), (2) Inadequate response or inability to tolerate methotrexate, (3) Inadequate response or inability to tolerate at least one NSAID (e.g. ibuprofen, naproxen, meloxicam, celecoxib) Hidradenitis Suppurativa (HS): (1) Diagnosis of HS.
<b>Age Restrictions</b>	(AS, nr-axSpA, HS): Member is 18 years of age or older. (PsO): Member is 6 years of age or older (PsA): Member is 2 years of age or older. (ERA): Member is 4 years of age or older.
<b>Prescriber Restrictions</b>	(PsO, HS): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (AS, nr-axSpA, ERA): Prescribed by or in consultation with a rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# CRESEMBA [ORAL] 2025

## Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Invasive Aspergillosis (IA): (1) For use in the treatment of invasive aspergillosis after inadequate response or inability to tolerate Voriconazole (oral Vfend). Mucormycosis (MC): (1) Diagnosis of invasive mucormycosis
<b>Age Restrictions</b>	(IA, MC): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(All Indications): Prescribed by or in consultation with an infectious disease specialist, oncologist, OR prescribed as part of chemotherapy prophylaxis protocol
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DALFAMPRIDINE 2025

## Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	MS (Initial): Member has history of seizure or moderate to severe renal impairment (CrCL less than or equal to 50 mL/min)
<b>Required Medical Information</b>	Multiple Sclerosis (MS) (Initial): (1) Diagnosis of multiple sclerosis. (2) Confirmation that member has difficulty walking.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(MS) (Initial and Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial, Reauth): Remainder of contract year
<b>Other Criteria</b>	(MS) (Reauth): Documentation of positive clinical response as evidenced by improvement in walking speed
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DAYVIGO 2025

---

## Products Affected

- DAYVIGO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Insomnia: (1) Diagnosis of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. (2) Inadequate response or inability to tolerate generic ramelteon (Rozerem) AND Belsomra (suvorexant).
<b>Age Restrictions</b>	(Insomnia): Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DEFERASIROX 2025 - Pending CMS Review

## Products Affected

- *deferasirox oral tablet*
- *deferasirox oral tablet soluble*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(NTDT, CIO-BT)(Initial, Continuation): GFR is less than 40mL/min/1.73m, platelet counts less than 50,000/mcL
<b>Required Medical Information</b>	Chronic Iron Overload in Non transfusion-dependent thalassemia (NTDT) (Initial): (1) Diagnosis of Chronic iron overload in Non transfusion-dependent thalassemia syndromes,(2) liver iron concentration (LIC) of at least 5 mg of iron per gram of liver dry weight (mg Fe/g dw), (3) serum ferritin greater than 300 mcg/L. (4) Serum ferritin levels consistently greater than 300 mcg/L (as demonstrated with at least two lab values within the previous two months). Chronic Iron Overload Caused by Blood Transfusions (CIO-BT)(Initial): (1) Diagnosis of chronic iron overload caused by blood transfusions (transfusional hemosiderosis). (2) Serum ferritin levels consistently greater than 1,000 mcg/L (as demonstrated with at least two lab values within the previous two months).
<b>Age Restrictions</b>	(NTDT)(Initial, Continuation): Member is 10 years of age or older. (CIO-BT) (Initial, Continuation): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial):3 months. (Continuation): 6 months
<b>Other Criteria</b>	(CIO-BT)(Continuation): (1) Decreased serum ferritin level compared with the baseline level for transfusion- dependent anemia. (NTDT)(Continuation): (1) Decreased serum ferritin level compared with the baseline level or reduction in LIC (liver iron concentration).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DIACOMIT 2025

---

## Products Affected

- DIACOMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet syndrome (DS): (1) Diagnosis of seizures associated with Dravet syndrome (DS), (2) Used in combination with clobazam.
<b>Age Restrictions</b>	Member is 6 months of age or older
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DICHLORPHENAMIDE 2025

## Products Affected

- ORMALVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Initial, Reauth): Concomitant use of high dose Aspirin, severe pulmonary disease and hepatic insufficiency
<b>Required Medical Information</b>	One of the following (1) Diagnosis of Primary hyperkalemic periodic paralysis, (2) Diagnosis of Primary hypokalemic periodic paralysis (3) Diagnosis of Paramyotonia Congenita with periodic paralysis
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Initial, Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial): 3 months (Reauth): Indefinite
<b>Other Criteria</b>	(Reauth): Member has had a positive clinical response to therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# DICLOFENAC 3% PRODUCTS 2025

---

## Products Affected

- *diclofenac sodium external gel 3 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Actinic Keratoses: (1) Diagnosis of Actinic Keratoses
<b>Age Restrictions</b>	Actinic Keratoses: Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	90 days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DICLOFENAC EPOLAMINE 2025

---

## Products Affected

- *diclofenac epolamine external*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Previously experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
<b>Required Medical Information</b>	(1): Inadequate response or inability to tolerate at least 2 prescription strength topical NSAIDs (i.e. Diclofenac Gel 1%, Diclofenac Topical Solution 1.5%)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# DOPTELET 2025

## Products Affected

- DOPTELET ORAL TABLET 20 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic Liver Disease (CLD): (1) Diagnosis of Chronic Liver Disease (CLD) (2) Baseline platelet count less than 50,000/mcL. Member is scheduled to undergo a procedure. Chronic Immune Thrombocytopenia (ITP)(Initial): (1) Baseline platelet count less than 30,000/mcL. (2) Inadequate response or inability to tolerate one of the following: (a) corticosteroids (b) immunoglobulins (c) splenectomy (d) Rituxan (rituximab)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ITP)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist
<b>Coverage Duration</b>	(CLD): 1 month. (ITP): 12 months
<b>Other Criteria</b>	(ITP)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	Yes

# DUPIXENT 2025

## Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE 200 MG/1.14ML, 300  
 MG/2ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent therapy with any other biologic agents
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Diagnosis of moderate-severe atopic dermatitis. (2) inadequate response or inability to tolerate TWO of the following: (a) one topical steroid (medium potency or higher), (b) topical tacrolimus, (c) topical pimecrolimus, (d) topical eucrisa (crisaborole). Asthma (Initial): (1) ONE of the following: (a) Member has oral corticosteroid-dependent asthma or (b) Member has blood eosinophil levels of at least 150 cells/mcL at baseline or at least 300 cells/mcL within the past 12 months, (2) ONE of the following: (a) Member has had at least one asthma exacerbation requiring systemic corticosteroids within the past 12 months, or (b) Any prior intubation for asthma exacerbation, or (c) prior asthma-related hospitalization within the past 12 months, (3) the requested medication will be used in addition to BOTH of the following: (a) medium to high dose inhaled corticosteroid (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND (b) one additional controller medication. Chronic Rhinosinusitis with Nasal Polyposis(CRSwNP)(Initial): (1) Diagnosis of chronic rhinosinusitis with nasal polyposis, (2) concurrent use of intranasal corticosteroid. Eosinophilic esophagitis (EoE)(Initial): (1) Diagnosis of eosinophilic esophagitis (EoE) (2) Member has symptoms of esophageal dysfunction (e.g. dysphagia, food impaction, gastroesophageal reflux disease [GERD]/heartburn symptoms, chest pain, abdominal pain (3) Member has at least 15 intraepithelial eosinophils per high power (HPF) (4) Other causes of esophageal eosinophilia have been excluded (5) Member weighs at least 15 kg (b) (6) Inadequate response or inability to tolerate at least an 8-week trial of one of the following: (a) proton pump inhibitors (e.g. pantoprazole, omeprazole (b) Topical (esophageal) corticosteroids (e.g. budesonide, fluticasone).
<b>Age Restrictions</b>	(Asthma)(Initial, Reauth): Member is 6 years old or older. (AD): Member is 6 months of age or older. (CRSwNP)(PN)(Initial, Reauth): Member is 18 years of age or older (EoE)(Initial, Reauth): Member is 1 year of age or older

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	(AD): Prescribed by/in consultation with a dermatologist, allergist, immunologist (Asthma)(Initial, Reauth): Prescribed by/in consultation with an allergist, immunologist or pulmonologist (CRSwNP)(Initial, Reauth): Prescribed by/in consultation with an allergist, immunologist or ENT specialist (EoE)(Initial, Reauth): Prescribed by/in consultation with gastroenterologist, allergist, or immunologist (PN)(Initial, Reauth): Prescribed by/in consultation with allergists/immunologist or dermatologist
<b>Coverage Duration</b>	(AD): Indefinite (Asthma, CRSwNP, EoE, PN) (Initial): 12 months (Reauth): 12 months
<b>Other Criteria</b>	Prurigo Nodularis (PN)(Initial): (1) Diagnosis of Prurigo Nodularis (PN) (2) inadequate response or inability to tolerate one medium or higher potency topical corticosteroid. (Asthma)(Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction in exacerbations, improvement in forced expiratory volume in 1 second [FEV1], decreased use of rescue medications) (2) the requested medication will be used in addition to BOTH of the following: (a) medium to high dose inhaled corticosteroid (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND (b) one additional controller medication. (CRSwNP) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction of nasal polyps score [NPS: 0-8 scale], improvement in nasal congestion/obstruction score [NC: 0-3 scale]), (2) Used in combination with another agent for CRSwNP. (EoE)(Reauth): (1) Documentation of a positive clinical response to therapy as evidenced by improvement of at least one of the following from baseline: (a)Symptoms (e.g. dysphagia, food impaction, heartburn, chest pain), (b) Histologic measures (e.g. esophageal intraepithelial eosinophil count), (c) Endoscopic measures (e.g. edema, furrows, exudates, rings, strictures). (PN)(Reauth): (1) Documentation of a positive clinical response to therapy (e.g. reduction in the number of nodular lesions from baseline, or improvement in symptoms from baseline)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EMFLAZA 2025

---

## Products Affected

- *deflazacort oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Duchenne Muscular Dystrophy (DMD): (1) Diagnosis of Duchenne Muscular Dystrophy (DMD) (2) Diagnosis confirmed by ONE of the following: (a) Mutation of the dystrophin gene (b) Absence of the dystrophin protein confirmed by muscle biopsy (3) Inadequate response or inability to tolerate prednisone or prednisolone
<b>Age Restrictions</b>	(DMD): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(DMD): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EMGALITY 2025

## Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Documentation of concomitant use with another injectable CGRP inhibitor.
<b>Required Medical Information</b>	Migraines (Initial): Approved when ONE of the following inclusion criteria are met: (1) Diagnosis of episodic migraines defined as 4 to 14 headache days per month AND inadequate response or inability to tolerate a 4 week trial of or contraindication to TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine. OR (2) Diagnosis of chronic migraines defined as greater than or equal to 15 headache days per month AND inadequate response or inability to tolerate a 4 week trial of or contraindication to TWO of the following prophylactic medications (i) topiramate (ii) divalproex sodium/ valproic acid (iii) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (iv) tricyclic antidepressants: amitriptyline, nortriptyline (v)SNRI antidepressants: venlafaxine, duloxetine (vi) candesartan. Episodic Cluster Headaches (ECH) (Initial): (1) Diagnosis of episodic cluster headache, (2) Member has experienced at least 2 cluster periods lasting 6 days to 365 days, separated by pain-free periods lasting at least three months
<b>Age Restrictions</b>	(Migraine, ECH)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(Migraine, ECH)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, pain specialist
<b>Coverage Duration</b>	(Migraine, ECH)(Initial): 6 months, (Migraine, ECH)(Reauth):12 months
<b>Other Criteria</b>	(Migraine)(REAUTH): (1) Response to therapy as defined by a reduction in headache days per month (defined as at least 4 hours duration and moderate intensity). (ECH)(REAUTH): (1) Response to therapy as defined by a reduction in weekly cluster headache attacks.
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No



# EMSAM 2025

---

## Products Affected

- EMSAM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Major depressive disorder (MDD): (1) Diagnosis of major depressive disorder. (2) Inadequate response or inability to tolerate ONE SSRI or SNRI. (3) 4-5 half-lives (approximately 1 week) has elapsed after discontinuation of antidepressants without long half-lives OR at least 5 weeks has elapsed after discontinuation with antidepressants with long half-lives (e.g. fluoxetine).
<b>Age Restrictions</b>	(MDD): Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENBREL 2025

## Products Affected

- ENBREL MINI SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML • ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, PJIA, PsO, AS): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate ONE DMARD: (e.g. Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine). Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least ONE DMARD: (e.g. Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine). Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of moderate to severe PJIA, (2) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Leflunomide, Sulfasalazine. Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe chronic PsO. Ankylosing Spondylitis (AS): (1) Diagnosis of AS, (2) Inadequate response or inability to tolerate one other treatment such as NSAIDs, COX2 inhibitors or methotrexate.
<b>Age Restrictions</b>	(PJIA, PsA): Member is 2 years of age or older. (RA, AS): Member is 18 years of age or older. (PsO): Member is 4 years of age or older
<b>Prescriber Restrictions</b>	(RA, PJIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (PsO): Prescribed by or in consultation with a dermatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ENDARI 2025

## Products Affected

- ENDARI
- *l-glutamine oral packet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Sickle Cell Disease (SCD)(Initial): (1) One of the following: (A) Member is using Endari with concurrent hydroxyurea therapy, OR (B) Member has an inadequate response or inability to tolerate hydroxyurea. (2) Member has had 2 or more painful sickle cell crises within the past 12 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(SCD)(Initial, Reauth): Prescribed by or in consultation with a hematologist or oncologist
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(Reauth): Documentation of positive clinical response to therapy (e.g. reduction in the number of sickle cell crises)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EPIDIOLEX 2025

## Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet Syndrome (DS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. (3) Concurrent use with additional anti-epileptic(s). Lennox-Gastaut Syndrome (LGS): (1) Inadequate response or inability to tolerate ONE of the following: (a) clobazam (b) valproic acid, or (c) topiramate. (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy. (3) Concurrent use with additional anti-epileptic(s). Tuberous Sclerosis Complex (TSC): (1) Concurrent use with additional anti-epileptic(s). (2) Baseline CBC, serum transaminases and total bilirubin prior to initiating therapy
<b>Age Restrictions</b>	(DS, LGS, TCS): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(DS, LGS, TCS): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ESBRIET 2025

---

## Products Affected

- ESBRIET
- *pirfenidone*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Idiopathic Pulmonary Fibrosis (IPF): (1) Diagnosis of IPF confirmed by high resolution CT scan or biopsy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(IPF): Prescribed by or in consultation a pulmonologist or lung transplant specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(REAUTH) (IPF): BOTH of the following (1) stabilization from baseline AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EUCRISA 2025 - Pending CMS Review

---

## Products Affected

- EUCRISA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD): (1) Diagnosis of mild to moderate atopic dermatitis (2) Inadequate response or inability to tolerate at least ONE of the following in patients 2 years of age or older: (a) topical tacrolimus OR topical pimecrolimus, OR (b) generic, prescription medium potency or higher topical steroid.
<b>Age Restrictions</b>	(AD): Member is 3 months of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EVENITY 2025

## Products Affected

- EVENITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary for: Post Menopausal Osteoporosis (PMO): (1) Diagnosis of PMO defined as ONE of the following: (a) Bone mineral density T-score less than or equal to -2.50 OR (b) Documented history of an osteoporotic non- collision fracture [e.g. vertebral, hip, nonvertebral]) AND (2) Member is at high risk of fracture as defined by one of the following: (a) Member has risk factors for a fracture (e.g. endocrine disorders, gastrointestinal disorders, use of medications associated with low bone mass or bone loss such as corticosteroids) OR (b) Inadequate response or inability to tolerate ONE of the following: (i) bisphosphonates, (ii) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs), OR (iv) Denosumab (Prolia). (3) Cumulative lifetime therapy does not exceed 12 months.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 months
<b>Other Criteria</b>	Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# EXTENDED RELEASE METFORMIN 2025 - Pending CMS Review

## Products Affected

- *metformin hcl er (mod)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(DM2)(Initial, Reauth): (1) Serum creatinine levels greater than or equal to 1.5 mg/dL in males, or serum creatinine levels greater than or equal to 1.4 mg/dL in females. (2) Hepatic impairment. (3) Metabolic acidosis, including diabetic ketoacidosis. (4) Used for preventing weight gain.
<b>Required Medical Information</b>	Diabetes Mellitus Type 2 (DM2)(Initial): (1) Diagnosis of DM2. (2) Member has a HgbA1C greater than 6.5%. All Indications: (1) Inadequate response or inability to tolerate a 12 week trial of both of the following: (a) Immediate release metformin, and (b) Extended-release metformin (generic Glucophage XR)
<b>Age Restrictions</b>	(DM2 for tablets) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial, Reauth): End of contract year.
<b>Other Criteria</b>	(DM2)(Reauth): Member has had a positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# EYSUVIS 2025

---

## Products Affected

- EYSUVIS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dry Eye Disease (DED)(Initial): (1) Diagnosis of DED (2) Trial and failure for a minimum 14 days duration of therapy, contraindication, or intolerance to 0.5% loteprednol suspension
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(DED)(Initial, Reauth): Prescribed by or in consultation with an ophthalmologist or optometrist.
<b>Coverage Duration</b>	(Initial, Reauth): 14 days
<b>Other Criteria</b>	(DED)(Reauth): (1) Positive clinical response to therapy (e.g. improvement in dry eye symptoms).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FASENRA 2025 - Pending CMS Review

## Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent therapy with any other biologic agents for asthma/allergic conditions (e.g. dupilumab [Dupixent], mepolizumab [Nucala], omalizumab [Xolair], reslizumab [Cinqair])
<b>Required Medical Information</b>	Part D is medically necessary when there is a documentation of the following: Severe Asthma (SA)(Initial): (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by ONE of the following at initiation of therapy (a) blood eosinophil levels are at least 150 cells/microliter if dependent on daily oral corticosteroids or (b) blood eosinophil levels are at least 300 cells/microliter AND, (2) ONE of the following: (a) Member has had at least one asthma exacerbation requiring systemic corticosteroids within the past 12 months, or (b) Any prior intubation for asthma exacerbation, or (c) prior asthma-related hospitalization within the past 12 months, AND (3) Member is currently treated with ONE of the following unless there is a contraindication or intolerance to these medications: (a) high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional asthma controller medication (e.g. leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline) OR (b) one maximally-dosed combination ICS/LABA product).
<b>Age Restrictions</b>	(SA)(Initial): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(SA)(Initial): Prescribed by or in consultation with pulmonologist or allergy/immunology specialist
<b>Coverage Duration</b>	(Initial): 12 months (Reauth): 12 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	Subject to Part B vs Part D review (SA) (Reauth): (1) Member is currently treated with ONE of the following unless there is a contraindication or intolerance to these medications: (a) high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional asthma controller medication (e.g. leukotriene receptor antagonist, long-acting beta-2 agonist (LABA), theophylline) OR (b) one maximally-dosed combination ICS/LABA product). (2) Positive clinical response to therapy (e.g. reduction in exacerbations, decreased use of rescue medications)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FENTANYL CITRATE LOZENGE 2025

## Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Documentation of all of the following: (1) pain associated with cancer, (2) long-acting pain medication regimen AND (3) member is opioid tolerant (e.g. at least one week where total daily dose is at least one of the following: 25mcg of transdermal fentanyl hourly, 30mg of oxycodone daily, 60mg of oral morphine daily, 8mg of oral hydromorphone daily, 25mg of oral oxymorphone daily or an equianalgesic dose of another opioid)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with one of the following: Pain specialist, Oncologist, Hematologist, Hospice care specialist, or Palliative care specialist.
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FERRIPROX 2025 - Pending CMS Review

## Products Affected

- *deferiprone*
- FERRIPROX ORAL TABLET 1000 MG
- FERRIPROX TWICE-A-DAY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Transfusional Iron Overload (TIO): (1) Diagnosis of transfusional iron overload due to one of the following: (a) Thalassemia syndromes, (b) sickle cell disease, (c) other transfusion-dependent anemias. (2) Inadequate response or inability to tolerate current chelation therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# FINTEPLA 2025

## Products Affected

- FINTEPLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dravet Syndrome (DS): Inadequate response or inability to tolerate ONE of the following: (a) clobazam, (b) valproic acid, (c) divalproex sodium, (d) topiramate. Lennox-Gastaut Syndrome (LGS): (1) Diagnosis of seizures associated with Lennox-Gastaut Syndrome (LGS) (2) Inadequate response or inability to tolerate ONE of the following: valproic acid, lamotrigine, topiramate, felbamate, clobazam.
<b>Age Restrictions</b>	(DS, LGS): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	(DS, LGS): Prescribed by or in consultation with a neurologist.
<b>Coverage Duration</b>	Indefinite.
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GALAFOLD 2025 - Pending CMS Review

## Products Affected

- GALAFOLD

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Fabry Disease (FD)(Initial): (1) Member has amenable galactosidase alpha gene (GLA) variant based on in vitro assay data (2) Will not be used in combination with enzyme replacement therapy for FD (e.g. agalsidase beta or pegunigalsidase alfa)
<b>Age Restrictions</b>	(FD)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(FD)(Initial, Reauth): Prescribed by or in consultation with a clinical genetics specialist OR a nephrologist
<b>Coverage Duration</b>	(Initial): 6 months, (Reauth): Indefinite
<b>Other Criteria</b>	(FD)(Reauth): (1) Positive clinical response to therapy (2) Will not be used in combination with enzyme replacement therapy for FD (e.g. agalsidase beta or pegunigalsidase alfa)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# GOCOVRI 2025

## Products Affected

- GOCOVRI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Dyskinesia in Parkinson's disease (DPD): (1) Diagnosis of PD (2) Member is experiencing dyskinesia. (3) Member is receiving levodopa based therapy (4) Inadequate response or inability to tolerate amantadine immediate-release. Parkinson's Disease with OFF episodes (PD with OFF episodes): (1) Diagnosis of Parkinson's disease. (2) Concurrent use of carbidopa/levodopa containing product. (3) Member is experiencing intermittent OFF episodes. (4) Member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(DPD, PD with OFF episodes): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# GROWTH HORMONES 2025 - Pending CMS Review

## Products Affected

- GENOTROPIN SUBCUTANEOUS CARTRIDGE
- HUMATROPE INJECTION CARTRIDGE
- NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 5 MG/1.5ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) Growth Failure in Children (GFC)(Initial): (A) Diagnosis of growth hormone deficiency confirmed by one of the following: (I) Height is documented by one of the following (utilizing age and gender growth charts related to height): (a) Height is greater than 2.0 standard deviations [SD] below midparental height (b) Height is greater than 2.25 SD below population mean (below the 1.2 percentile for age and gender) (II) Growth velocity is greater than 2 SD below mean for age and gender (III) Delayed skeletal maturation of greater than 2 SD below mean for age and gender (e.g., delayed is greater than 2 years compared with chronological age), (B) documentation of bone age, (C) abnormal response from provocative testing, such as insulin-induced hypoglycemia test, levodopa, or clonidine. (2) Small for Gestational Age (SGA)(Initial): (A) Diagnosis of SGA, (B) Clinical documentation of no catch-up growth by 2 to 4 years of age. (3) Growth Failure Associated with Chronic Kidney Disease (GF-CKD) (Initial), (4) Growth failure associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or short stature homeobox-containing gene (SHOX) deficiency (Initial), (5) Diagnostically confirmed Growth Hormone Deficiency in adults (GHDA)(Initial), OR (6) Idiopathic Short Stature (ISS)(Initial): (A) Diagnosis of ISS defined by height standard deviation score (SDS) less than or equal to 2.25, (B) Documentation of growth velocity less than 25th percentile for bone age.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(All Other Indications)(Initial): Prescribed by or in consultation with an endocrinologist. (GF-CKD)(Initial) : Prescribed by or in consultation with an endocrinologist or nephrologist
<b>Coverage Duration</b>	(Initial, Continuation): 12 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	(GHDA)(Continuation): Annual clinical re-evaluation by the treating endocrinologist. (GFC)(Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist (SGA, ISS)(Continuation): (1) Increase in growth velocity from baseline, (2) Annual clinical re-evaluation by the treating endocrinologist. (GF-CKD)(Continuation): (1) No history of renal transplant, (2) Annual clinical re-evaluation by the treating endocrinologist. (Growth Failure Associated with Noonan Syndrome, Prader-Willi Syndrome, Turner Syndrome or Short Stature Homeobox-Containing Gene (SHOX) Deficiency)(Continuation): (1) Annual clinical re-evaluation by the treating endocrinologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HAEGARDA 2025

---

## Products Affected

- HAEGARDA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hereditary Angioedema (HAE): (1) Diagnosis of hereditary angioedema (HAE), (2) For prophylaxis against HAE attacks.
<b>Age Restrictions</b>	(HAE): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(HAE): Prescribed by or in consultation with an allergist, immunologist, pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HIGH DOSE OPIOIDS 2025

## Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr, 25 mcg/hr, 37.5 mcg/hr*
- *fentanyl transdermal patch 72 hour 50 mcg/hr, 75 mcg/hr*
- *hydromorphone hcl er oral tablet extended release 24 hour 12 mg, 8 mg*
- *hydromorphone hcl oral tablet 4 mg, 8 mg*
- *methadone hcl oral tablet*
- *morphine sulfate er oral capsule extended release 24 hour 80 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 60 mg*
- *oxycodone hcl oral tablet 30 mg*
- *oxymorphone hcl er oral tablet extended release 12 hour 30 mg*
- *XTAMPZA ER*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NEW TO HIGH DOSE OPIOID THERAPY : ONE of the following (A) pain associated with cancer, (B) chronic non-cancer pain and BOTH of the following (1) member is opioid tolerant (e.g. at least one week where total daily dose is at least one of the following: 30mg of oxycodone, 60mg of oral morphine, 8mg of oral hydromorphone, 25mg of oral oxymorphone or an equianalgesic dose of another opioid) AND (2) the member has been evaluated for non-opioid prescription pharmacologic treatment prior to initiation of high dose opioid therapy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable. CONTINUING HIGH DOSE OPIOID THERAPY (morphine equivalent dose 90mg per day or greater): ONE of the following (1) pain associated with cancer OR (2) chronic non-cancer pain and ALL (a) member's pain has been assessed within the last 6 months AND (b) member has clinically meaningful improvement in pain and functioning that outweighs risks to patient safety AND (c) member is not being treated for substance abuse
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM 2025

## Products Affected

- *butalbital-acetaminophen oral tablet 50-325 mg*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-aspirin-caffeine oral capsule*
- *dipyridamole oral*
- *metaxalone*
- *promethazine hcl oral solution*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM CYCLOBENZAPRINE 2025 - Pending CMS Review

## Products Affected

- *cyclobenzaprine hcl er oral capsule extended release 24 hour 15 mg*
- *cyclobenzaprine hcl oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Acute Muscle Spasms (AMS): (1) Diagnosis of Acute Muscle Spasms (AMS):(2) Prescriber attestation that drug will be used only for short periods. All Indications: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly.
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	AMS: 1 year. Other dx: 2 yearsPoly-ACH DUR: 1 year
<b>Other Criteria</b>	Subject to additional clinical review for Poly-ACH cDUR related use - if applicable. (1) The drug is being prescribed for a medically accepted indication (2) The prescriber acknowledges anticholinergic risks (e.g., confusion, dry mouth, blurry vision, constipation, urinary retention) (3) The prescriber will consider lowering the dose or discontinuing medication(s) that are no longer clinically warranted for the member
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM ESTROGENS 2025

## Products Affected

- CLIMARA PRO *mg/24hr, 0.075 mg/24hr*
- DOTTI • JINTELI
- *estradiol transdermal patch twice weekly* • MENOSTAR
- *estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr* • PREMARIN ORAL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ONE of the following: (1) Inadequate response or inability to tolerate vaginal estrogen preparations (e.g. vaginal tablets or cream, etc.) OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	2 years
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM KETOROLAC 2025

---

## Products Affected

- *ketorolac tromethamine oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ONE of the following: (1) Inadequate response or inability to tolerate TWO alternative NSAIDs such as meloxicam, naproxen, celecoxib, ibuprofen, etc. OR (2) Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	One Month
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# HRM NON BENZODIAZEPINE HYPNOTICS 2025

## Products Affected

- *eszopiclone oral tablet 3 mg*
- *zolpidem tartrate er oral tablet extended release 12.5 mg*
- *zolpidem tartrate oral tablet 10 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Initial): Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly
<b>Age Restrictions</b>	(Initial, Reauth): Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 3 months. (Reauth): 2 years
<b>Other Criteria</b>	(REAUTH): Prescriber is aware of the risk versus benefit of using the medication chronically (greater than 90 days)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# HRM SHORT TERM SKELETAL MUSCLE RELAXANTS 2025 - Pending CMS Review

---

## Products Affected

- *carisoprodol oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Acute Muscle Spasms (AMS): (1) Diagnosis of Acute Muscle Spasms (AMS):(2) Prescriber attestation that drug will be used only for short periods. All Indications: Risk versus benefit has been assessed for this request of a high risk medication (HRM) in elderly.
<b>Age Restrictions</b>	Apply if member is greater than or equal to 65 years
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(AMS): 1 year. (All other indications): 2 years
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ILUMYA 2025

---

## Products Affected

- ILUMYA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB), (b) Enbrel, (c) Skyrizi, (d) Cosentyx, (e) Stelara, (f) Otezla OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(PsO): Member is 18 years of age or older.
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INBRIJA 2025

## Products Affected

- INBRIJA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PD): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INCRELEX 2025

## Products Affected

- INCRELEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(GHGD, PIGF-1D) (Initial and Continuation): Known or suspected malignancy, closed epiphyses, concurrent GH therapy
<b>Required Medical Information</b>	Growth Hormone Gene Deletion (GHGD): (Initial) (1) Diagnosis of growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. Severe Primary IGF-1 Deficiency (PIGF-1D): (Initial) (1) Diagnosis of Severe primary IGF-1 deficiency AND (2) height standard deviation score less than or equal to -3.0 AND (3) basal IGF-1 standard deviation score less than or equal to -3.0 AND normal or elevated growth hormone.
<b>Age Restrictions</b>	(GHGD, PIGF-1D) (Initial and Continuation): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(GHGD, PIGF-1D) (Initial and Continuation) Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	(Initial and continuation): 12 months
<b>Other Criteria</b>	(GHGD, PIGF-1D)(CONTINUATION): (1) Documentation of increase in growth velocity from baseline AND (2) Annual clinical re-evaluation by an endocrinologist AND (3) BOTH of the following: (a) Expected adult height is not obtained (b) documentation of expected adult height goal
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INGREZZA 2025

## Products Affected

- INGREZZA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD) (Initial): (1) Diagnosis of moderate to severe tardive dyskinesia (2) documentation of baseline AIMS and (3) one of the following: (a) persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication, or (b) member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Chorea- Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD) (Initial, Reauth): Prescribed by or in consultation with a neurologist or a psychiatrist
<b>Coverage Duration</b>	(TD) (Initial): 3 months (TD)(Reauth): indefinite (CHD): Indefinite
<b>Other Criteria</b>	(TD) (Reauthorization): Valbenazine (Ingrezza) is reapproved with documentation of positive clinical response, as demonstrated by improvement in AIMS, to Ingrezza therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INHALED TOBRAMYCIN 2025

---

## Products Affected

- TOBI PODHALER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of cystic fibrosis AND (2) evidence of P. aeruginosa in the lungs (3) FEV1 between 25% and 80%, (4) Member not colonized with Burkholderia cepacia.
<b>Age Restrictions</b>	(CF): Member is 6 years of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with a pulmonologist, infectious disease specialist or Specialist affiliated with a CF care center.
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# INJECTABLE METHOTREXATE 2025

## Products Affected

- OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML
- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of severe, active rheumatoid arthritis (RA), (2) Inadequate response or inability to tolerate oral methotrexate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate oral methotrexate. Polyarticular juvenile idiopathic arthritis (pJIA): (1) Diagnosis of pJIA, (2) Inadequate response or inability to tolerate oral methotrexate. Psoriasis: (1) Diagnosis of severe psoriasis, (2) Inadequate response to BOTH of the following: (a) oral methotrexate AND (b) topical steroids (e.g. clobetasol propionate cream/ointment, betamethasone cream/ointment, etc.).
<b>Age Restrictions</b>	(Psoriasis): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, pJIA): Recommended by rheumatologist. (PSA): Recommended by a rheumatologist or dermatologist. (Psoriasis): Recommended by dermatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# INTRAVENOUS IMMUNE GLOBULINS (IVIG) 2025

## Products Affected

- GAMMAGARD INJECTION SOLUTION 2.5 GM/25ML
- GAMMAGARD S/D LESS IGA
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- OCTAGAM INTRAVENOUS SOLUTION 1 GM/20ML, 2 GM/20ML
- PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Initial): History of hypersensitivity (including anaphylaxis or severe systemic reaction) to immune globulin or any component of the preparation.
<b>Required Medical Information</b>	Part D is medically necessary when ONE of the following is present: (1) Autoimmune mucocutaneous blistering disease pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane (cicatrical) pemphigoid , benign mucous membrane pemphigoid, epidermolysis bullosa acquisita and ONE of the following: (a) inadequate response or inability to tolerate conventional therapy (i.e. steroids, immunosuppressants) OR (b) rapidly progressive disease in conjunction with conventional therapy (i.e. steroids, immunosuppressants). (2) Acute Idiopathic Thrombocytopenia Purpura (ITP) and ONE of the following (a) management of acute bleeding (b) used to increase platelet count prior to surgical procedures) (c) severe thrombocytopenia (platelets less than 20, 000 per uL) or (d) high risk for intracerebral hemorrhage. (3) Chronic ITP and ALL of the following (a) inadequate response or inability to tolerate corticosteroids (b) duration of illness greater than 6 months (c) platelets persistently less than 20,000/ uL. (4) Chronic B-cell lymphocytic leukemia with IgG less than 600mg/dL and recurrent, serious bacterial infections requiring antibiotic therapy. (5) Hematopoietic stem cell transplant and IgG less than 400mg/dL. (6) HIV and all of the following (a) less than 14 years of age (b) evidence of qualitative or quantitative humoral immunologic defects and (c) current bacterial infection despite antimicrobial prophylaxis. (7) Solid organ transplant. (8) Chronic Inflammatory Demyelinating Polyneuritis confirmed by electrodiagnostic testing or nerve biopsy and an inadequate response or inability to tolerate corticosteroids. (9) Dermatomyositis or Polymyositis diagnosed by laboratory testing (antinuclear or myositis specific antibodies), biopsy, EMG, or MRI) and inadequate response or inability to tolerate steroids or immunosuppressants. (10) Guillain Barre syndrome with impaired function (i.e. unable to stand or walk without aid).
<b>Age Restrictions</b>	

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with a physician who has specialized expertise in managing patients on immune globulin therapy (e.g. immunologist, hematologist, neurologist).
<b>Coverage Duration</b>	(All Indications): 6 months
<b>Other Criteria</b>	Subject to Part B vs Part D review. (11) Lambert Eaton myasthenic syndrome and an inadequate response or inability to tolerate steroids, immunosuppressants, or cholinesterase inhibitors (12) Multifocal motor neuropathy diagnosed by electrodiagnostic studies. (13) Acute exacerbations of multiple sclerosis (MS) unresponsive to steroids. (14) Myasthenia gravis and an inadequate response or inability to tolerate at least 8 weeks of standard therapy (e.g. corticosteroids, azathioprine, cyclosporine, cyclophosphamide, cholinesterase inhibitors) (15) Myasthenic crisis (16) Stiff person syndrome and an inadequate response or inability to tolerate standard therapy (e.g. muscle relaxants, benzodiazepines, and gabapentin-related medications) (17) Severe, active SLE and an inadequate response or inability to tolerate steroids (18) Kawasaki disease. (19) Infections in Low-birthweight Neonates when severe hypogammaglobulinemia (IgG greater than or equal to 400 mg/dL) is present. (20) Graves' Ophthalmopathy (21) Immune mediated Necrotizing Myopathy when resistant to treatment with glucocorticoids and immunosuppressants (22) Graves disease (All Indications)(CONTINUATION): (1) Documentation of clinical improvement as appropriate to the diagnosis (e.g. clinical improvement in symptoms, Rankin score and Activities of Daily Living (ADL) scores, etc.)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KALYDECO 2025

---

## Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of Cystic Fibrosis with documentation of one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data, (2) Mutation was documented by an FDA-cleared CF mutation test to detect the presence of the CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions.
<b>Age Restrictions</b>	(CF): Member is 1 month of age or older for granules. Member is 6 years of age or older for tablets
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with is a pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KERENDIA 2025

## Products Affected

- KERENDIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic kidney disease associated with type 2 diabetes (CKD with T2D): (1) Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D), (2) One of the following (a) Minimum 30-day trial of a maximally tolerated dose and member will continue therapy with ONE of the following (i) generic angiotensin-converting enzyme (ACE) inhibitor (e.g. benazepril, lisinopril), (ii) generic angiotensin II receptor blocker (ARB) (e.g. losartan, valsartan), (b) Member has contraindication or intolerance to ACE inhibitors or ARBs
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KEVZARA 2025

## Products Affected

- KEVZARA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PMR): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB), (b) etanercept (Enbrel), (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Polymyalgia Rheumatica (PMR): (1) Diagnosis of polymyalgia rheumatica (2) Inadequate response or inability to tolerate corticosteroids (e.g. prednisone)
<b>Age Restrictions</b>	(RA, PMR): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, PMR): Prescribed by or in consultation with a rheumatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KINERET 2025

## Products Affected

- KINERET SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, NOMID, DIRA): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid Arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB), (b) etanercept (Enbrel), (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Neonatal-Onset Multisystem Inflammatory Disease (NOMID): (1) Diagnosis of NOMID. (2) Diagnosis has been confirmed by one of the following: (a) NLRP-3 (nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Auto-inflammatory Syndrome-1 [CIAS1]) mutation (b) Evidence of active inflammation including both of the following: (i) clinical symptoms (e.g. rash, fever, arthralgia) (ii) elevated acute phase reactants (e.g. ESR, CRP). Deficiency of Interleukin-1 Receptor Antagonist (DIRA): (1) Diagnosis of DIRA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(RA, NOMID, DIRA): Prescribed by or in consultation with a rheumatologist or pediatric specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# KORLYM 2025

---

## Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(HCS): Pregnancy
<b>Required Medical Information</b>	Hyperglycemia in members with Cushing Syndrome (HCS): (1) Hyperglycemia secondary to hypercortisolism in adult member with endogenous Cushing syndrome, (2) member has type 2 diabetes mellitus or glucose intolerance, (3) member has failed surgery or is not a candidate for surgery.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(HCS): Prescribed by or in consultation with an endocrinologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LETAIRIS 2025

## Products Affected

- LETAIRIS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. (4) Inadequate response or inability to tolerate ambrisentan
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# LIDOCAINE TRANSDERMAL PATCH 2025 - Pending CMS Review

---

## Products Affected

- *lidocaine external patch 5 %*
- LIDOCAN
- TRIDACAINE II

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Post-Herpetic Neuralgia (PHN): (1) Diagnosis of post-herpetic neuralgia. Diabetic Peripheral Neuropathy (DPN): (1) Diagnosis of diabetic peripheral neuropathy.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# LIVTENCITY 2025 - Pending CMS Review

## Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cytomegalovirus (CMV): (1) Diagnosis of cytomegalovirus (CMV) infection/disease, (2) Member is a recipient of one of the following (a) Hematopoietic stem cell transplant, (b) solid organ transplant, (3) Inadequate response to a minimum 2 weeks duration or inability to tolerate one of the following therapies at an appropriately indicated dose (a) intravenous (IV) ganciclovir, (b) oral valganciclovir, (c) intravenous (IV) foscarnet, (d) intravenous (IV) cidofovir, (4) Member weighs greater than or equal to 35kg
<b>Age Restrictions</b>	(CMV): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(CMV): Prescribed by or in consultation with a provider who specializes in one of the following areas (1) transplant, (2) infectious disease (3) Oncology
<b>Coverage Duration</b>	8 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# MODAFINIL 2025 - Pending CMS Review

## Products Affected

- *modafinil oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>NARCOLEPSY: (1) Diagnosis of Narcolepsy confirmed by a sleep study (unless prescriber provides justification that a sleep study is not feasible).</p> <p>OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME (OSAHS): (1) Diagnosis confirmed by a sleep study (unless prescriber provides justification confirming that a sleep study is not feasible). (2) Both of the following (a): 5 or more obstructive respiratory events per hour of sleep confirmed by a sleep study (unless the prescriber provides justification confirming that a sleep study is not feasible) AND (b) One of the following symptoms: Unintentional sleep episodes during wakefulness, or daytime sleepiness, or unrefreshing sleep, or fatigue, or insomnia, or waking up breath holding, gasping, or choking, or loud snoring, or breathing interruptions during sleep. SHIFT WORK SLEEP DISORDER (SWSD): (1) One of the following: (a) Symptoms of excessive sleepiness or insomnia for at least 3 months, which is associated with a work period (usually night work) that occurs during the normal sleep period, OR (b) A sleep study demonstrating loss of a normal sleep-wake pattern (i.e., disturbed chronobiologic rhythmicity). (2) Documentation that the member has no other medical or mental disorder accounting for the symptoms.</p> <p>Multiple Sclerosis (MS) Related Fatigue: (1) Diagnosis of Multiple Sclerosis (MS) related fatigue (All Indications): Inadequate response or inability to tolerate generic modafinil</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Narcolepsy, SWSD, OSAHS): Prescribed by or in consultation with a neurologist or sleep specialist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

# NEXLETOL/NEXLIZET 2025

## Products Affected

- NEXLETOL
- NEXLIZET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Heterozygous Familial Hypercholesterolemia (HeFH) OR Atherosclerotic Cardiovascular Disease (ASCVD) (Initial): (1) One of the following: (A) Diagnosis of HeFH, OR (B) Diagnosis of ASCVD as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid). (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after at least 8 weeks of one low, moderate or high-intensity statin therapy and member will continue to receive statin therapy at maximally tolerated dose OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks. (3) One of the following: (A) Member has been receiving at least 8 weeks of ezetimibe (Zetia) therapy as adjunct to maximally tolerated statin therapy OR (B) Member has contraindication or intolerance to ezetimibe (Zetia).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months
<b>Other Criteria</b>	(HeFH, ASCVD) (Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) One of the following: (A) Member continues to receive other lipid-lowering therapy (e.g. statins, ezetimibe) at the maximally tolerated dose OR (B) Member has inability to tolerate other lipid-lowering therapy (e.g. statins, ezetimibe)
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

# NON-ORAL CHEMO AGENTS 2025

## Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy. Subject to Part B vs Part D review.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NON-PREFERRED GLP-1 AGONISTS 2025

## Products Affected

- BYDUREON BCISE SOLUTION PEN-INJECTOR
- BYETTA 10 MCG PEN SUBCUTANEOUS SOLUTION PEN-INJECTOR
- BYETTA 5 MCG PEN SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(DM2): (1) One of the following: (a) For members requiring ongoing treatment for type 2 diabetes mellitus, submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus (b) Submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values (i) A1C greater than or equal to 6.5 percent (ii) Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL (iii) 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during OGTT (oral glucose tolerance test) (2) Inadequate response or inability to tolerate a minimum 90 day-supply of two of the following preferred brands: Ozempic, Trulicity, Rybelsus, Mounjaro, Victoza
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# NOURIANZ 2025

---

## Products Affected

- NOURIANZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Parkinson's Disease (PD): (1) Diagnosis of Parkinson's disease. (2) concurrent use of carbidopa/levodopa containing product, (3) Member is experiencing intermittent OFF episodes, (4) member had inadequate response or inability to tolerate ONE of the following: (a) MAO-B inhibitor (e.g. rasagiline, selegiline), (b) Dopamine agonist (e.g. pramipexole, ropinirole), (c) COMT inhibitor (e.g. entacapone)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PD): Prescribed by or in consultation with a neurologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NOXAFIL 2025 - Pending CMS Review

## Products Affected

- *posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Treatment of invasive aspergillosis (TAI): Diagnosis of TAI. Prophylaxis of Invasive Aspergillus Infections (AI): (1) For use in prophylaxis of invasive Aspergillus infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend). Prophylaxis of Invasive Candida Infections(CI): (1) For use in prophylaxis of invasive Candida infection due to being severely immunocompromised after inadequate response or inability to tolerate voriconazole (Vfend).
<b>Age Restrictions</b>	(TAI): Member is 13 years of age or older. (AI, CI): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(All Indications): Prescribed by or in consultation with an infectious disease specialist, transplant specialist, hematologist, oncologist, OR prescribed as part of chemotherapy prophylaxis protocol
<b>Coverage Duration</b>	Remainder of contract year
<b>Other Criteria</b>	Subject to additional clinical review for ESRD-related use - if applicable.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUCALA 2025

## Products Affected

- NUCALA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(SA, EGPA, CRSwNP) Concurrent therapy with any other biologics for asthma/allergic conditions (e.g. benralizumab [Fasenra], dupilumab [Dupixent], omalizumab [Xolair], reslizumab [Cinqair])
<b>Required Medical Information</b>	Part D is medically necessary when there is documentation of ONE of the following: Severe Asthma with Eosinophilic Phenotype (SA) (Initial): (1) Diagnosis of severe asthma with eosinophilic phenotype as defined by one of the following: a) blood eosinophil levels are at least 150 cells/microliter at initiation of therapy (measured within 6 weeks of dosing), or b) blood eosinophil levels at least 300 cells/microliter within the past 12 months. (2) Member has had at least two or more asthma exacerbations requiring systemic corticosteroids within the past 12 months OR member has had any prior intubation for an asthma exacerbation OR Member has had a prior asthma-related hospitalization within the past 12 months, AND Member is currently treated with high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500 mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g. long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. Eosinophilic Granulomatosis with Polyangiitis (EGPA) (Initial): (1) Diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA), (2) Member's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy), and (3) Member is currently receiving corticosteroid therapy (e.g. prednisolone, prednisone). Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (Initial): (1) Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP). (2) Unless contraindicated, the member has had an inadequate response to at least a 2 month treatment with an intranasal corticosteroid (e.g. fluticasone, mometasone). (3) Used in combination with intranasal corticosteroid for CRSwNP.
<b>Age Restrictions</b>	(SA) (Initial, Reauth): Member is 6 years of age or older. (HES) (Initial, Reauth): Member is 12 years of age or older. (CRSwNP, EGPA) (Initial, Reauth): Member is 18 years of age or older.

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	(SA): Prescribed by or in consultation with pulmonologist or allergy/immunology specialist. (EGPA): Prescribed by or in consultation with a rheumatologist. (HES): Prescribed by or in consultation with either allergist/immunologist or hematologist. (CRSwNP): Prescribed by or in consultation with allergist, immunologist, otolaryngologist or pulmonologist.
<b>Coverage Duration</b>	(Initial): 12 months. (Reauth): 12 months.
<b>Other Criteria</b>	Subject to Part B vs Part D review. Hyper eosinophilic Syndrome (HES) (Initial): (1) Diagnosis of HES. (2) All of the following: (a) Member has been diagnosed for at least 6 months, (b) Verification that other non-hematologic secondary causes have been ruled out (e.g. drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy), (c) member is FIP1-like1-platelet derived growth factor receptor alpha kinase (FIP1L1-PDGFR kinase)-negative. (3) Member has uncontrolled HES defined by both of the following: (a) Pre-treatment blood eosinophil count greater than or equal to 1000 cells/microliter, (b) Member has experienced 2 or more flares within the past 12 months. (4) Inadequate response or inability to tolerate one of the following: (a) corticosteroid therapy (e.g. prednisone), (b) cytotoxic/immunosuppressive therapy (e.g. hydroxyurea, cyclosporine, imatinib). (SA)(Reauth): (1) Member is currently treated with high-dose inhaled corticosteroids (ICS) (e.g. greater than or equal to 500mcg fluticasone propionate equivalent/day) AND an additional controller medication (e.g. long-acting beta agonist such as salmeterol or formoterol, leukotriene inhibitor such as montelukast, theophylline), unless the individual is intolerant of or has a contraindication to two of the additional controller agents. (EGPA) (Reauth): (1) Positive clinical response to therapy (e.g. increase in remission time). (HES) (Reauth): (1) Positive clinical response (e.g. reduction in corticosteroid use, reduction of blood eosinophil count, reduction in flares). (CRSwNP) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction of nasal polyps score [NPS: 0-8 scale], improvement in nasal obstruction symptoms via visual analog scale [VAS: 0-10 scale]), (2) Used in combination with intranasal corticosteroid for CRSwNP.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUEDEXTA 2025 - Pending CMS Review

## Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PBA): Presence of Prolonged QT interval, Congenital long QT Syndrome, or Torsades de pointes documented by a cardiac test (e.g. electrocardiogram)
<b>Required Medical Information</b>	Pseudobulbar Affect (PBA): (1) Diagnosis of Pseudobulbar affect (2) Member has one of the following underlying conditions: (a) Amyotrophic lateral sclerosis (b) Multiple sclerosis (c) Alzheimer's disease (d) Parkinson's disease (e) Stroke (f) Traumatic brain injury
<b>Age Restrictions</b>	(PBA): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PBA): Prescribed by or in consultation with a neurologist or psychiatrist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NUPLAZID 2025

---

## Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hallucinations and Delusions Parkinson Disease Psychosis (HDPDP): Inadequate response or inability to tolerate ONE of the following (a) quetiapine or (b) clozapine.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# NURTEC 2025

## Products Affected

- NURTEC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AM)(Initial, Reauth): Medication will be used in combination with another oral CGRP inhibitor. (MP) (Initial, Reauth): Medication used in combination with another CGRP inhibitor for the preventive treatment of migraines.
<b>Required Medical Information</b>	Acute Treatment of Migraines (AM)(Initial): (1) Diagnosis of migraine with or without aura in adults. (2) Member has fewer than 15 headache days per month. (3) inadequate response or inability to tolerate ONE generic formulary triptan. Preventative Treatment of Migraines (MP) (Initial): (1) Diagnosis of episodic migraines defined as 4 to 18 migraine days per month AND inadequate response or inability to tolerate a 4 week trial of TWO of the following prophylactic medications (a) topiramate (b) divalproex sodium/ valproic acid (c) beta-blocker: metoprolol, propranolol, timolol, atenolol, nadolol (d) tricyclic antidepressants: amitriptyline, nortriptyline (e)SNRI antidepressants: venlafaxine, duloxetine, (f) (candesartan).
<b>Age Restrictions</b>	(AM)(MP)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(AM)(MP)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist.
<b>Coverage Duration</b>	(AM)(MP)(Initial): 6 months. (AM)(MP)(Reauth): 12 months
<b>Other Criteria</b>	(AM)(REAUTH): (1) Positive response to therapy (e.g. reduction in pain, photophobia, phonophobia, nausea). (MP)(Reauth): (1) Positive clinical response to therapy (e.g. reduction in headache frequency and/or intensity, use of acute migraine medications [e.g. nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, naproxen), triptans (e.g. eletriptan, rizatriptan, sumatriptan)] has decreased since the start of CGRP therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OCALIVA 2025

## Products Affected

- OCALIVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Primary biliary cholangitis (PBC): (1) Diagnosis of Primary biliary cholangitis (PBC) (2) Used in combination with ursodeoxycholic acid (e.g. Urso, Urso Forte, ursodiol), OR (2) inability to tolerate ursodeoxycholic acid. (3) Member has one of the following: (a) no cirrhosis or (b) compensated cirrhosis with no evidence of portal hypertension.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PBC) (Initial, Reauth): Prescribed by or in consultation with a hepatologist or gastroenterologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauth): Indefinite
<b>Other Criteria</b>	(PCB)(Reauth): Positive clinical response to Ocaliva therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# OFEV 2025

## Products Affected

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Idiopathic Pulmonary Fibrosis (IPF): (1) Diagnosis of IPF confirmed by high resolution CT scan or biopsy. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): (1) Diagnosis of SSc-ILD confirmed by a high resolution CT scan or biopsy. Chronic Fibrosing Interstitial Lung Disease (ILDs) with progressive phenotype (Initial): (1) Confirmed by high resolution CT scan (HRCT) showing at least 10% of lung volume with fibrotic features, (2) Disease has a progressive phenotype as observed by one of the following: (a) decline of forced vital capacity (FVC), (b) worsening of respiratory symptoms, (c) increased extent of fibrosis seen on imaging.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(IPF, SSc-ILD, ILDs): Prescribed by or in consultation a pulmonologist or lung transplant specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(REAUTH) (IPF, ILDs, SSc-ILD): BOTH of the following (1) stabilization from baseline AND (2) no elevations in AST or ALT greater than 5 times upper limit of normal or greater than 3 times upper limit of normal with signs or symptoms of severe liver damage
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OLUMIANT 2025 - Pending CMS Review

## Products Affected

- OLUMIANT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, Alopecia Areata): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists, JAK inhibitors, or potent immunosuppressants such as azathioprine, cyclosporine
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB), (b) Enbrel (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Alopecia Areata (AA): (1) Diagnosis of alopecia areata (2) Member has at least 50% scalp hair loss (3) Other causes of hair loss have been ruled out (e.g. androgenetic alopecia, trichotillomania, tinea capitis, psoriasis) (4) Inadequate response or inability to tolerate one previous treatment for alopecia areata (e.g. topical, intralesional, or systemic corticosteroids, topical immunotherapy)
<b>Age Restrictions</b>	(RA, Alopecia Areata): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA): Prescribed by or in consultation with a rheumatologist (AA): Prescribed by or in consultation with a dermatologist
<b>Coverage Duration</b>	(RA, Alopecia Areata): Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ONYCHOMYCOSIS AGENTS 2025

## Products Affected

- JUBLIA
- *tavaborole*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Onychomycosis: (1) Diagnosis of onychomycosis of the toenail(s) due to <i>Trichophyton rubrum</i> and <i>Trichophyton mentagrophytes</i> . (2) Diagnosis confirmed by one of the following: (a) positive potassium hydroxide (KOH) preparation, (b) culture, or (c) histology. (3) Condition is causing debility or a disruption in member's activities of daily living. (4) Inadequate response or inability to tolerate BOTH of the following: (a) oral generic terbinafine, AND (b) oral generic itraconazole OR topical generic ciclopirox.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	1 year
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OPZELURA 2025

## Products Affected

- OPZELURA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Atopic Dermatitis (AD) (Initial): (1) For short-term, non-continuous treatment of chronic atopic dermatitis. (2) Inadequate response or inability to tolerate at least TWO of the following: (a) topical tacrolimus OR topical pimecrolimus, OR (b) generic, prescription medium potency or higher topical steroid, OR (c) Eucrisa. (3) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g. azathioprine or cyclosporine). Nonsegmental Vitiligo (NV)(Initial): (1) Diagnosis of nonsegmental vitiligo (2) Inadequate response or inability to tolerate one of the following (a) medium or higher potency topical corticosteroid (b) pimecrolimus cream (c) tacrolimus ointment (3) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g. azathioprine or cyclosporine).
<b>Age Restrictions</b>	(AD, NV): Member is 12 years of age or older
<b>Prescriber Restrictions</b>	(AD) (Initial, Reauth): Prescribed by or in consultation with a dermatologist or allergist/immunologist (NV) (Initial, Reauth): Prescribed by or in consultation with a dermatologist.
<b>Coverage Duration</b>	(AD)(Initial): 8 Weeks, (Reauth): End of contract year (NV)(Initial): 6 months, (Reauth): 12 months
<b>Other Criteria</b>	(AD) (Reauth): Positive clinical response to therapy. (NV)(Reauth): (1) Documentation of positive clinical response to therapy (2) Will not be used in combination with therapeutic biologics, other Janus kinase inhibitors, or potent immunosuppressants (e.g. azathioprine or cyclosporine).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL CHEMO AGENTS 2025

---

## Products Affected

- *abiraterone acetate* 420 MG
- AKEEGA
- ALECENSA
- ALUNBRIG ORAL TABLET
- AUGTYRO
- AYVAKIT
- BALVERSA
- *bexarotene*
- BOSULIF ORAL CAPSULE 50 MG
- BOSULIF ORAL TABLET
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA
- CABOMETYX
- CALQUENCE ORAL TABLET
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DAURISMO
- ERIVEDGE
- ERLEADA
- *erlotinib hcl*
- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*
- FOTIVDA
- FRUZAQLA
- GAVRETO
- *gefitinib*
- GILOTRIF
- GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate*
- IMBRUVICA ORAL CAPSULE
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET 140 MG, 280 MG,
- INLYTA
- INQOVI
- INREBIC
- IWILFIN
- JAKAFI
- JAYPIRCA
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KOSELUGO
- KRAZATI
- *lapatinib ditosylate*
- *lenalidomide*
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LONSURF
- LORBRENA
- LUMAKRAS
- LYNPARZA ORAL TABLET
- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)
- MEKINIST
- MEKTOVI
- NERLYNX
- NINLARO
- NUBEQA
- ODOMZO
- OGSIVEO
- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET 100 MG
- OJJAARA
- ONUREG
- ORGOVYX
- ORSERDU
- *pazopanib hcl*

- PEMAZYRE
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- QINLOCK
- RETEVMO
- REVLIMID
- REZLIDHIA
- ROZLYTREK
- RUBRACA
- RYDAPT
- SCEMBLIX
- *sorafenib tosylate*
- SPRYCEL
- STIVARGA
- *sunitinib malate*
- SUTENT
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID ORAL CAPSULE 100 MG, 50 MG
- TIBSOVO
- TRUQAP
- TUKYSA
- TURALIO ORAL CAPSULE 125 MG
- VANFLYTA
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI
- VIZIMPRO
- VONJO
- VOTRIENT
- WELIREG
- XALKORI
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG
- XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI
- ZEJULA ORAL TABLET
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET
- ZYTIGA

PA Criteria	Criteria Details
Exclusion Criteria	

PA Criteria	Criteria Details
<b>Required Medical Information</b>	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORAL PAH AGENTS 2025

## Products Affected

- OPSUMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ORENCIA SQ 2025 - Pending CMS Review

## Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, pJIA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Rheumatoid arthritis (RA): (1) Diagnosis of RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD. Polyarticular Juvenile idiopathic arthritis (pJIA): (1) Diagnosis of JIA. (2) Inadequate response or inability to tolerate one of the following: methotrexate, leflunomide, sulfasalazine.
<b>Age Restrictions</b>	(pJIA, PsA): Member is 2 years of age or older. (RA): member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, pJIA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ORKAMBI 2025

---

## Products Affected

- ORKAMBI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(CF): Diagnosis of CF other than those homozygous for the F508del mutation
<b>Required Medical Information</b>	Cystic Fibrosis (CF): (1) Diagnosis of CF, (2) Member is homozygous for the F508del mutation in the CFTR gene (3) If the member's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene
<b>Age Restrictions</b>	(CF): Member is 1 year of age or older
<b>Prescriber Restrictions</b>	(CF): Prescribed by or in consultation with pulmonologist or Specialist affiliated with a CF care center
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OTEZLA 2025 - Pending CMS Review

## Products Affected

- OTEZLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Oral Ulcers Associated with Bechet's Disease (OU-BD): (1) Diagnosis of OU-BD. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Plaque psoriasis (PsO): (1) Diagnosis of PsO.
<b>Age Restrictions</b>	(OU-BD): Member is 18 years of age or older. (PsA, PsO) Member is 6 years of age and older.
<b>Prescriber Restrictions</b>	(PsA, OU-BD): Prescribed by or in consultation with a Rheumatologist or Dermatologist. (PsO): Prescribed by or in consultation with dermatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# OXERVATE 2025

## Products Affected

- OXERVATE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Neurotrophic keratitis (NK)(Initial): (1) Diagnosis of NK. (2) Submission of chart documentation indicating treatment of left eye, right eye, or both
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(NK) (Initial, Reauth) Prescribed by or in consultation with an ophthalmologist or Optometrist.
<b>Coverage Duration</b>	8 weeks
<b>Other Criteria</b>	(NK)(Reauth): (1)Submission of chart documentation indicating treatment of left eye, right eye, or both, (2) Member has received less than or equal to 8 weeks of therapy (one course of therapy) per affected eye(s), (3) Documentation of clinical rationale for treatment greater than 8 weeks (e.g. member has a recurrence of neurotrophic keratitis, or treatment of a different eye), (4) Documentation of clinical response to prior Oxervate therapy, (5) Member will not exceed a total of 16 weeks of Oxervate therapy per affected eye(s).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PART D VS EXCLUDED 2025

---

## Products Affected

- INTRAROSA
- OSPHENA
- *voriconazole intravenous*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to additional clinical review for ESRD-related use - if applicable.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# PDE INHIBITOR AGENTS FOR PAH 2025

## Products Affected

- *tadalafil (pah)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV, (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography, (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion, (4) inadequate response or inability to tolerate generic tadalafil (Applies to Brand Adcirca only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(Initial): Prescribed by or in consultation with Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months (Reauth): 12 months
<b>Other Criteria</b>	(PAH)(Reauth): (1) Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PRALUENT 2025

## Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia, (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks</p> <p>Atherosclerotic cardiovascular disease (ASCVD) (Initial): (1) Diagnosis of atherosclerotic cardiovascular disease (ASCVD) as diagnosed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid), (2) ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months (Continuation): 12 months

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Homozygous Familial Hypercholesterolemia (HoFH) (Initial): (1) Diagnosis of HoFH. (2) One of the following: (a) Untreated LDL-C greater than 500 mg/dL or (b) Treated LDL-C greater than 300 mg/dL. (3) Member is receiving other lipid-lowering therapy (e.g. statin, ezetimibe). (4) Not used in combination with Juxtapid (lomitapide). (HLA, ASVCD)(CONTINUATION): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (HoFH)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) Member continues to receive other lipid-lowering therapy (e.g. statin, ezetimibe). (3) Not used in combination with Juxtapid (lomitapide).</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# PREFERRED GLP-1 AGONISTS 2025

## Products Affected

- OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML
- OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(DM2): (1) One of the following: (a) For members requiring ongoing treatment for type 2 diabetes mellitus, submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus (b) Submission of medical records (e.g. chart notes) confirming diagnosis of type 2 diabetes mellitus as evidenced by one of the following laboratory values (i) A1C greater than or equal to 6.5 percent (ii) Fasting plasma glucose (FPG) greater than or equal to 126 mg/dL (iii) 2-hour plasma glucose (PG) greater than or equal to 200 mg/dL during OGTT (oral glucose tolerance test)
<b>Age Restrictions</b>	N/A
<b>Prescriber Restrictions</b>	N/A
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	N/A
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PREFERRED HEPATITIS C AGENTS 2025

## Products Affected

- EPCLUSA
- HARVONI ORAL PACKET
- HARVONI ORAL TABLET 90-400 MG
- MAVYRET
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(1) Documentation of member's Hepatitis C Genotype. (2) Prescribed regimen is consistent with the current AASLD/IDSA guidance.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Duration will be applied consistent with AASLD/ IDSA guidance
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROLIA 2025

## Products Affected

- PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Part D is medically necessary when all of the following criteria are met:</p> <p>Osteoporosis (OS) (Initial): ALL of the following: (1) Diagnosis of osteoporosis confirmed by one of the following: (a) T-score less than or equal to -2.5 (b) history of osteoporotic fracture (e.g. vertebral, hip, non-vertebral) or (c) multiple risk factors for fracture. (2) ONE of the following: (a) inadequate response or inability to tolerate at least one other osteoporosis medicine (e.g. oral bisphosphonates, calcitonin, estrogens, selective estrogen receptor modulator (SERMs)) or (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted or (c) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less). Osteopenia (OPN) (Initial): BOTH of the following: (1) Diagnosis of osteopenia confirmed by a T-score less than -1.0, but greater than -2.5. (2) One of the following: (a) Member is receiving adjuvant aromatase inhibitor therapy for breast cancer (b) member is receiving androgen deprivation therapy for non-metastatic prostate cancer. Prophylaxis of Postmenopausal Osteoporosis (PO) (Initial): BOTH of the following: (1) BMD T score less than -1.0 and greater than -2.5. (2) ONE of the following: (a) Inadequate response or inability to tolerate an oral bisphosphonates or a selective estrogen receptor modulator (SERMs) or (b) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less) not receiving dialysis or diagnosed with stage 5 kidney disease.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	Subject to Part B vs Part D review. Glucocorticoid Induced Osteoporosis (GCO)(Initial): ALL of the following: (1) Diagnosis of CGO in men or women. (2) Daily dose of prednisone is greater than or equal to 5mg for at least 3 months. (3) ONE of the following: (a)Inadequate response or inability to tolerate ONE of the following: (i) bisphosphonates, (ii) hormone replacement therapy, (iii) selective-estrogen receptor modulators (SERMs)., (b) severely deteriorated condition indicating that the osteoporosis is so significant that a trial of oral bisphosphonates is not medically warranted, (c) documented moderate to severe renal insufficiency (glomerular filtration rate [GFR] 30 to 35 ml/min or less)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# PROMACTA 2025

## Products Affected

- PROMACTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Chronic Idiopathic Thrombocytopenic Purpura (ITP)(Initial): (1) Diagnosis of relapsed/refractory, persistent, or chronic ITP. (2) Baseline platelet count is less than 30,000/mcL. (3) Member's degree of thrombocytopenia and clinical condition increase the risk of bleeding. (4) Inadequate response or inability to tolerate ONE of the following: (a) corticosteroids, (b) immune globulin, (c) splenectomy. First-Line for Severe Aplastic Anemia(FLSAA): (1) Diagnosis of severe aplastic anemia. (2) Used for first-line treatment (i.e., member has not received prior immunosuppressive therapy). (3) Member meets at least TWO of the following: (a) absolute neutrophil count less than 500/mcL, (b) platelet count less than 20,000/mcL, (c) absolute reticulocyte count less than 60,000/mcL. (4) Used in combination with standard immunosuppressive therapy (e.g. Atgam [antithymocyte globulin equine] and cyclosporine). Refractory Severe Aplastic Anemia (RSAA)(Initial): (1) Diagnosis of refractory severe aplastic anemia. (2) Member has a platelet count less than 30,000/mcL. (3) Inadequate response or inability to tolerate immunosuppressive therapy with antithymocyte globulin and cyclosporine. Chronic Hepatitis C-Associated Thrombocytopenia (HEPC-TP): (1) Diagnosis of chronic hepatitis C-associated thrombocytopenia. (2) One of the following: (a) Planning to initiate and maintain interferon-based treatment, or (b) currently receiving interferon-based treatment.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ITP, FLSAA, RSAA)(Initial, Continuation): Prescribed by or in consultation with hematologist/oncologist. (HEPC-TP)(Initial, Continuation): Prescribed by or in consultation with Hematologist/oncologist, Gastroenterologist, Hepatologist, Infectious disease specialist, HIV specialist.
<b>Coverage Duration</b>	(ITP)Initial,Cont.=12mo.(FLSAA)=6mo.(RSAA)Initial=6mo.(HEPC-TP)Initial=3mo.(RSAA,HEPC-TP)Cont.=12mo.

PA Criteria	Criteria Details
<b>Other Criteria</b>	(ITP, RSAA)(Continuation): (1) Positive clinical response to therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinically important bleeding. (HEPC-TP)(Continuation): (1) ONE of the following: (A) For members that started treatment with Promacta prior to initiation of treatment with interferon, both of the following: (i) Member is currently on antiviral interferon therapy for treatment of chronic hepatitis C, AND (ii) member reached a threshold platelet count that allows initiation of antiviral interferon therapy with Promacta treatment by week 9. (B) For members that started treatment with Promacta while on concomitant treatment with interferon, member is currently on antiviral interferon therapy for treatment of chronic hepatitis C.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# QUALAQUIN 2025

## Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Use for treatment or prevention of nocturnal leg cramps
<b>Required Medical Information</b>	Uncomplicated Malaria: (1) Diagnosis of uncomplicated malaria due to (a) plasmodium falciparum malaria or (b) plasmodium vivax . (2) One of the following: (a) Both of the following: (i) treatment in areas of chloroquine-sensitive malaria (ii) Inadequate response or inability to tolerate chloroquine or hydroxychloroquine, or (b)treatment in areas of chloroquine-resistant malaria. Babesiosis: (1) Diagnosis of babesiosis.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	Babesiosis: 10 days Uncomplicated Malaria: 14 Days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RADICAVA 2025

---

## Products Affected

- RADICAVA ORS STARTER KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Amyotrophic Lateral Sclerosis (ALS)(Initial): (1) Diagnosis of definite or probable ALS per the revised El Escorial World Federation of Neurology criteria. (2) Normal respiratory function defined as forced vital capacity (FVC) of greater than or equal to 80% at the start of treatment. (3) Scores of 2 points or greater on each individual item of the ALS Functional Rating Scale-revised (ALSFRS-R).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(ALS)(Initial and Reauth): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(Initial, Reauth): 6 months.
<b>Other Criteria</b>	(ALS)(Reauth): (1) Member shows benefit from therapy (e.g. slowing of decline of functional abilities).
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# REPATHA 2025

## Products Affected

- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Hyperlipidemia (HLA) (Initial): (1) Diagnosis of hyperlipidemia. Atherosclerotic cardiovascular disease (ASCVD)(Initial): (1) Diagnosis of ASCVD confirmed by either stress test, angiography, atherosclerotic event (e.g. MI, angina, stroke, claudication, carotid stenosis) or arterial intervention for atherosclerotic disease (e.g. coronary, peripheral, carotid). (HLA, ASCVD) (Initial): ONE of the following: (A) LDL-C 70 mg/dL or greater after a minimum 8-week trial of at least moderate-intensity statin therapy OR (B) Inability to tolerate statin therapy as documented by one of the following: (i) member had rhabdomyolysis or symptoms with creatine kinase (CK) exceeding 10 times the upper limit of normal (ULN) or (ii) either of the following with TWO statins: myalgia (no CK elevation) or myositis (CK less than 10 times ULN or (iii) hepatotoxicity from statin use (increased AST/ALT exceeding 3 times ULN) or (iv) liver disease documented by Child Pugh A or worse OR AST/ALT exceeding 3 times ULN for at least 6 weeks.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months.
<b>Other Criteria</b>	Homozygous Familial Hypercholesterolemia (HoFH) (Initial): (1) Diagnosis of HoFH. (2) One of the following: (a) Untreated LDL-C greater than 500 mg/dL or (b) Treated LDL-C greater than 300 mg/dL. (3) Member is receiving other lipid-lowering therapy (e.g. statin, ezetimibe). (4) Not used in combination with Juxtapid (lomitapide). (HLA, ASCVD)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (HoFH)(Continuation): (1) Positive Clinical response to therapy (e.g. reduction in LDL-C levels). (2) Member continues to receive other lipid-lowering therapy (e.g. statin, ezetimibe). (3) Not used in combination with Juxtapid (lomitapide).
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

# RESPIRATORY ENZYMES 2025

---

## Products Affected

- PROLASTIN-C INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	(ATT): (1) IgA deficiency with known anti-IgA antibody.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	Subject to Part B vs Part D review.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# REZUROCK 2025 - Pending CMS Review

## Products Affected

- REZUROCK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Chronic graft-versus-host disease (cGVHD) (Initial): (1) Diagnosis of chronic graft-versus-host disease, (2) Inadequate response or inability to tolerate two or more lines of systemic therapy (e.g. corticosteroids, mycophenolate, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(cGVHD) (Initial/Reauth): Prescribed by or in consultation with one of the following (1) Hematologist, (2) Oncologist, (3) physician experienced in the management of transplant patients
<b>Coverage Duration</b>	(Initial/Reauth): 12 months
<b>Other Criteria</b>	(cGVHD) (Reauth): (1) Member does not show evidence of progressive disease while on therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# RINVOQ 2025 - Pending CMS Review

## Products Affected

- RINVOQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, AD, UC, AS, nr-AxSPA, CD, PJIA): Concurrent use with any other biologic disease modifying antirheumatic drug (DMARD), other JAK inhibitors, or potent immunosuppressants (e.g. azathioprine, cyclosporine).
<b>Required Medical Information</b>	<p>Rheumatoid Arthritis (RA): (1) Diagnosis of moderate to severely active RA. (2) Member has inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine (3) Member had inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB) OR documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate at least one DMARD (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine) (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB) or documentation demonstrating that a trial may be inappropriate. Atopic Dermatitis (AD): (1) Diagnosis of moderate to severe atopic dermatitis, (2) Inadequate response of or inability to tolerate at least TWO of the following: (a) medium or higher potency topical corticosteroid, (b) pimecrolimus cream, (c) Topical tacrolimus cream, (d) Eucrisa (crisaborole) ointment (3) Inadequate response or inability to tolerate at least one systemic drug product for the treatment of atopic dermatitis (examples include, but are not limited to Dupixent, Adbry or documentation that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of Ulcerative Colitis (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine). (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Humira, Adalimumab-ADB) or documentation demonstrating that a trial may be inappropriate.</p>
<b>Age Restrictions</b>	(RA, UC, AS, nr-AxSPA, CD): Member is 18 years of age or older (AD): Member is 12 years of age or older. (PsA, PJIA): Member is 2 years of age or older

PA Criteria	Criteria Details
<b>Prescriber Restrictions</b>	(RA, AS, nr-AxSPA, PJIA): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (AD): Prescribed by or in consultation with a dermatologist, allergist, immunologist. (UC, CD): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	<p>Ankylosing Spondylitis (AS): (1) Diagnosis of active ankylosing spondylitis. (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB) OR documentation demonstrating that a trial may be inappropriate. Non-radiographic axial spondylarthritis (nr-AxSPA): (1) Diagnosis of nr-AxSPA (2) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB, Cimzia) or documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID. Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, methotrexate, azathioprine or 6-mercaptopurine) (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB) OR documentation demonstrating that a trial may be inappropriate.</p> <p>Polyarticular Juvenile Idiopathic Arthritis (PJIA): (1) Diagnosis of active PJIA, (2) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine (3) Member had an inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, adalimumab-ADB), or documentation demonstrating that a trial may be inappropriate.</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SIGNIFOR 2025

## Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cushing's disease (CD)(Initial): (1) Diagnosis of (pituitary) Cushing's disease. (2) Pituitary surgery is not an option or has not been curative
<b>Age Restrictions</b>	(CD)(Initial): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CD)(Initial, Reauth): Prescribed by or in consultation with an endocrinologist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CD)(Reauth): Documentation of positive clinical response (e.g. clinically meaningful reduction in 24- hour urinary free cortisol levels, improvement in signs or symptoms of the disease)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SILDENAFIL 2025

## Products Affected

- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PAH, RP): Documentation of concomitant nitrate use
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH): (1) Diagnosis of PAH WHO Group I with New York Heart Association (NYHA) Functional Class II to IV (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography (3) Mean pulmonary artery pressure greater than or equal 25 mm Hg at rest or greater than 30 mm Hg with exertion. Raynaud's Phenomenon (RP): (1) Diagnosis of secondary Raynaud's phenomenon. (2) Inadequate response or inability to tolerate a calcium channel blocker.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH, RP): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# SIMPONI 2025 - Pending CMS Review

## Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AS, PsA, RA, UC): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB), (b) etanercept (Enbrel), (c) secukinumab (Cosentyx), (d) tofacitinib (Xeljanz/Xeljanz XR), (e) upadacitinib (Rinvoq) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e., Humira, Adalimumab-ADB), (b) Enbrel, (c) Xeljanz/Xeljanz XR, (d) Rinvoq, (e) Skyrizi, (f) Cosentyx, (g) Stelara, (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Rheumatoid arthritis (RA): (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB), (b) Enbrel, (c) Rinvoq, (d) Xeljanz/Xeljanz XR, (e) Orencia OR documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate two of the following: (a) Adalimumab (i.e. Humira, Adalimumab-ADB), and (b) Xeljanz/Xeljanz XR, (c) Stelara, (d) Rinvoq OR documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(AS, PsA, RA, UC): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(RA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a rheumatologist or dermatologist. (UC): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No

# SIRTURO 2025

## Products Affected

- SIRTURO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB): (1) Diagnosis of MDR-TB. (2) Member weighs at least 15kg (applies to members 5 to less than 18 years of age). (3) One of the following: (a) Medication will be used in combination with at least 3 other drugs to which the member's MDR-TB isolate has been shown to be susceptible in vitro OR (b) If in vitro testing results are unavailable, treatment will be initiated in combination with at least 4 other drugs to which the member's MDR-TB isolate is likely to be susceptible. (4) Sirturo (bedaquiline) will be administered by directly observed therapy (DOT).
<b>Age Restrictions</b>	(MDR-TB): Member is 5 years of age or older.
<b>Prescriber Restrictions</b>	(MDR-TB): Prescribed by or in consultation with infectious disease specialist or pulmonologist
<b>Coverage Duration</b>	24 weeks
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# SKYRIZI SC 2025

## Products Affected

- SKYRIZI PEN
- SKYRIZI SUBCUTANEOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA, CD): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Plaque psoriasis (PsO):Diagnosis of moderate to severe PsO. Psoriatic Arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least ONE DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine). Crohn's Disease (CD): (1) Diagnosis of CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, methotrexate, azathioprine or 6-mercaptopurine). (3) Used only for maintenance therapy following induction therapy with the IV formulation.
<b>Age Restrictions</b>	(PsO, PsA, CD): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation a dermatologist (PsA): Prescribed by or consultation with a rheumatologist or dermatologist (CD): Prescribed by or in consultation with a gastroenterologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Part B drug applies only to beneficiaries enrolled in an MA-PD plan.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# STELARA SQ 2025 - Pending CMS Review

## Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(CD, UC, PsA, PsO): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), e.g. tumor necrosis factor antagonists
<b>Required Medical Information</b>	Part D is medically necessary when: Plaque psoriasis (PsO): Diagnosis of moderate to severe PsO. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least one DMARD. Crohn's Disease (CD): (1) Diagnosis of moderate to severe CD. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, Aminosalicylate, azathioprine or 6-mercaptopurine). Ulcerative Colitis (UC): (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate at least ONE conventional treatment: (e.g. corticosteroid, methotrexate, azathioprine or 6-mercaptopurine).
<b>Age Restrictions</b>	(CD, UC): Member is 18 years of age or older. (PsO, PsA): Member is 6 years of age or older.
<b>Prescriber Restrictions</b>	(CD, UC): prescribed by or in consultation with a Gastroenterologist. (PsO): prescribed by or in consultation with a Dermatologist. (PsA): prescribed by or in consultation with a Dermatologist or Rheumatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TAFAMIDIS 2025

## Products Affected

- VYNDAMAX
- VYNDAQEL

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM)(Initial): (1) Diagnosis of ATTR-CM confirmed by one of the following: (a) Member has a transthyretin (TTR) mutation (e.g. V122I), (b) cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of TTR amyloid deposits, or (c) all of the following: echocardiogram or cardiac magnetic resonance image suggestive of amyloidosis, scintigraphy scan suggestive of cardiac TTR amyloidosis, and absence of light-chain amyloidosis, (2) One of the following: (a) History of heart failure (HF), with at least one prior hospitalization for HF, or (b) presence of clinical signs and symptoms of HF (e.g. dyspnea, edema), (3) Member has New York Heart Association (NYHA) Functional Class I, II, or III heart failure
<b>Age Restrictions</b>	(ATTR-CM) (Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(ATTR-CM) (Initial, Reauth): Prescribed by or in consultation with a cardiologist
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(ATTR-CM)(Reauth): (1) Positive clinical response to therapy, (2) Member continues to have NYHA Functional Class I, II, or III heart failure.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TALTZ 2025

## Products Affected

- TALTZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA, AS, nr-axSpA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	<p>Plaque Psoriasis (PsO): (1) Diagnosis of moderate to severe PsO. (2) ONE of the following: (A) For members 6 to 17 years of age: an inadequate response or inability to tolerate two of the following: (a) Enbrel, (b) Cosentyx, (c) Stelara or documentation demonstrating that a trial may be inappropriate, OR (B) For members 18 years of age or older: an inadequate response or inability to tolerate two of the following: (a)Cosentyx (b) Enbrel (c) Adalimumab (i.e. Humira, Adulimumab-ADB) (d) Skyrizi, (e) Stelara, (f) Otezla or documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate TWO of the following: (a) Enbrel (b) Adalimumab(i.e. Humira, Adulimumab-ADB) (c) Cosentyx (d) Rinvoq (e) Skyrizi (f) Stelara (g) Xeljanz/Xeljanz XR, (h) Orencia, (i) Otezla OR documentation demonstrating that a trial may be inappropriate. Ankylosing spondylitis (AS): (1) Diagnosis of AS. (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adulimumab-ADB), (b) etanercept (Enbrel), (c) secukinumab (Cosentyx), (d) upadacitinib (Rinvoq), (e) tofacitinib (Xeljanz/Xeljanz XR) OR documentation demonstrating that a trial may be inappropriate. Non-Radiographic Axial Spondyloarthritis (nr-axSpA): (1) Diagnosis of nr-axSpA. (2) Inadequate response or inability to tolerate Rinvoq OR Cosentyx OR documentation demonstrating that a trial may be inappropriate (3) Inadequate response or inability to tolerate one NSAID (e.g. ibuprofen, meloxicam, naproxen).</p>
<b>Age Restrictions</b>	(PsA, AS, nr-axSpA): Member is 18 years of age or older. (PsO): Member is 6 years of age or older.
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (AS, nr-axSpA): Prescribed by or in consultation with a rheumatologist.
<b>Coverage Duration</b>	Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# TAVNEOS 2025

## Products Affected

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) (ANCA-V(GPA)(MPA))(Initial): (1) Diagnosis of Severe Active Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated Vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]) AND 2) Used as adjunct to standard therapy, and glucocorticoids
<b>Age Restrictions</b>	(ANCA-V(GPA)(MPA))(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(ANCA-V(GPA)(MPA))(Initial, Reauth): Prescribed by or in consultation with a nephrologist, pulmonologist, or rheumatologist.
<b>Coverage Duration</b>	(Initial): 6 Months (Reauth): 1 year
<b>Other Criteria</b>	(ANCA-V(GPA)(MPA))(Reauth): (1) Positive clinical response to therapy defined as sustained remission as assessed by the Birmingham Vasculitis Activity Score (BVAS). (2) Used as adjunct to standard therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TEGSEDI 2025

## Products Affected

- TEGSEDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(Initial, Continuation): 1) A history of liver transplant or is likely to be a candidate and 2) used in combination with any other RNA interference agents (e.g. transthyretin stabilizers)
<b>Required Medical Information</b>	Polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis)(Initial): (1) Diagnosis of hATTR amyloidosis with polyneuropathy confirmed by molecular genetic testing that reveals pathogenic variation(s) in the TTR gene (e.g. variation of V30M). (2) ONE of the following baseline ambulation parameters in either the Familial Amyloid Polyneuropathy (FAP) Stage or Polyneuropathy Disability (PND) Score (a) Stage 1 (unimpaired ambulation) or 2 (assisted ambulation) on the Familial Amyloid Polyneuropathy (FAP) staging tool, or (b) Score I, II, IIIa, or IIIb on the Polyneuropathy Disability (PND) scoring tool. (3) Documented presence of cardiac or renal manifestations, or motor, sensory, or autonomic neuropathy related to the hATTR amyloidosis with polyneuropathy (e.g. neuropathic pain, muscle weakness that affects daily living, orthostatic hypotension, diarrhea, nausea, vomiting, heart failure, arrhythmias, proteinuria, renal failure, vision disorders, such as vitreous opacity, dry eyes, glaucoma, or pupils with an irregular or scalloped appearance)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(hATTR Amyloidosis)(Initial, Continuation): Prescribed by or in consultation with a neurologist, geneticist, or professional provider specializing in the treatment of amyloidosis
<b>Coverage Duration</b>	(Initial): 16 months. (Continuation): Indefinite

PA Criteria	Criteria Details
<b>Other Criteria</b>	(hATTR Amyloidosis)(Continuation): (1) Documented improvement or stability in the signs and symptoms hATTR amyloidosis with polyneuropathy (e.g. neuropathic pain, muscle weakness that affects daily living, orthostatic hypotension, diarrhea, nausea, vomiting, heart failure, arrhythmias, proteinuria, renal failure, vision disorders, such as vitreous opacity, dry eyes, glaucoma, or pupils with an irregular or scalloped appearance), based on objective or standard evaluation scales, and (2) ONE of the following: (a) Stage 1 (unimpaired ambulation) or 2 (assisted ambulation) on the Familial Amyloid Polyneuropathy (FAP) staging tool, or (b) Score I, II, IIIa, or IIIb on the Polyneuropathy Disability (PND) scoring tool
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TERIPARATIDE 2025

## Products Affected

- FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR 600 MCG/2.4ML
- *teriparatide subcutaneous solution pen-injector 620 mcg/2.48ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Primary or Hypogonadal Osteoporosis (HGO)(Initial): (1) Diagnosis of HGO in men. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T-score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. low-trauma fracture of the hip, spine, pelvis, or distal forearm, etc.). (3) Inadequate response or inability to tolerate (a) bisphosphonates or (b) hormone replacement therapy.</p> <p>Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. low-trauma fracture of the hip, spine, pelvis, or distal forearm, etc.). (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia).</p>
<b>Age Restrictions</b>	(HGO, PMO, GCO) (Initial and Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial and Reauth): Remainder of contract year

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>Glucocorticoid Induced Osteoporosis (GCO)(Initial): (1) Diagnosis of CGO in men or women. (2) Daily dose of prednisone is greater than or equal to 5mg for at least 3 months. (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), or (d) Denosumab (Prolia). (HGO, PMO, GCO) (Reauth): One of the following: (1) Cumulative lifetime therapy does not exceed 2 years [applies to Teriparatide and Forteo], OR (2) member remains at or has returned to having a high risk for fracture despite a total of 24 months of use of parathyroid hormones [applies to Forteo only].</p>
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TESTOSTERONE PRODUCTS 2025

## Products Affected

- JATENZO
- testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml
- testosterone enanthate intramuscular solution
- testosterone transdermal gel 10 mg/act (2%), 12.
- 5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)
- testosterone transdermal solution
- XYOSTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Delayed Puberty (DP): (1) Diagnosis of delayed puberty in male members (Applies to Testosterone Enanthate only). Breast Cancer (BC): (1) Diagnosis of inoperable breast cancer in female members (Applies to Testosterone Enanthate only) (2) Used for palliative treatment Hypogonadism (HG)(New starts only): (1) Attestation that diagnosis was initially confirmed by ALL of the following: (A) Two early morning total testosterone levels below 300 ng/dL measured on separate occasions, (B) Normal Prolactin Level, and (C) Physical or cognitive symptoms of testosterone deficiency (e.g. physical: fatigue, sleep disturbances, decreased activity, cognitive: depressive symptoms, cognitive dysfunction, loss of concentration, poor memory, irritability), (2) ONE of the following (A) negative history of prostate and breast cancer OR (B) Both of the following (i) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (ii) documentation that the risk versus benefit has been assessed.
<b>Age Restrictions</b>	(HG) Member is 12 years of age or older (applies to generic testosterone cypionate only) and member is 18 years of age or older for all other products
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(DP, BC): Indefinite (HG)(New Starts, Continuation): Indefinite
<b>Other Criteria</b>	(HG)(Continuation): ONE of the following (1) negative history of prostate and breast cancer OR (2) Both of the following (a) history of prostate cancer with stable PSA less than or equal to 4ng/dL for 2 years and (b) documentation that the risk versus benefit has been assessed
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

PA Criteria	Criteria Details
<b>Part B Prerequisite</b>	No

# TOPICAL CHEMO AGENTS 2025

## Products Affected

- *bexarotene*
- VALCHLOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Approved when ANY of the following inclusion criteria is met: (1) Drug is FDA approved for indication and regimen requested, (2) The indication and regimen is classified as Category 1 or 2A by National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, (3) narrative text in The American Hospital Formulary Service-Drug Information (AHFS-DI) or Clinical Pharmacology Compendium is supportive for the specific condition(s) requested, (4) The Micromedex Compendium and the strength of recommendation is listed as Class I, Class IIa, or Class IIb for the specific condition(s) requested, (5) Indication is listed in Lexi-Drugs as "off label" with evidence level A, (6) supported by Peer-Reviewed Medical Literature as defined in Chapter 15 Section 50.4.5 of the Medicare Benefit Policy Manual
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	Prescribed by or in consultation with an oncologist or dermatologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	(All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# TOPICAL RETINOID PRODUCTS 2025

---

## Products Affected

- *tretinoin external*

PA Criteria	Criteria Details
Exclusion Criteria	Cosmetic use
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Remainder of contract year
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# TRACLEER 2025

## Products Affected

- *bosentan*
- TRACLEER

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. (4) Inadequate response or inability to tolerate bosentan (applies to brand Tracleer only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH) (Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist.
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation):12 months.
<b>Other Criteria</b>	(PAH)(Continuation): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TREMFYA 2025

## Products Affected

- TREMFYA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE 100 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PsO, PsA): Concurrent therapy with biological DMARDs or other tumor necrosis factor antagonists
<b>Required Medical Information</b>	Plaque psoriasis (PsO): (1) Diagnosis or moderate to severe PsO. (2) Inadequate response or inability to tolerate two of the following: (a) Cosentyx, (b) Enbrel, (c) Adalimumab (i.e. Humira, Adulimumab-ADB), (d) Skyrizi, (e) Stelara, (f) Otezla OR documentation demonstrating that a trial may be inappropriate. Psoriatic arthritis (PsA): (1) Diagnosis of PsA, (2) Inadequate response or inability to tolerate TWO of the following: (a) Adalimumab (i.e. Humira, Adulimumab-ADB) (b) Enbrel (c) Cosentyx (d) Rinvoq (e) Skyrizi (f) Stelara (g) Xeljanz/Xeljanz XR, (h) Orencia, (i) Otezla or documentation demonstrating that a trial may be inappropriate.
<b>Age Restrictions</b>	(PsO, PsA): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PsO): Prescribed by or in consultation with a dermatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TYMLOS 2025

## Products Affected

- TYMLOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>Postmenopausal Osteoporosis (PMO) (Initial): (1) Diagnosis of PMO. (2) Member has severe osteoporosis or is at a high to very high risk for fracture as defined by ONE of the following: (a) Member has a history of multiple vertebral fractures, (b) T score of the individual's bone mineral density (BMD) is at least -2.5 standard deviations below the young adult mean OR (c) history of osteoporotic fracture (i.e. Low-trauma fracture of the hip, spine, pelvis, or distal forearm, etc.) (3) Inadequate response or inability to tolerate ONE of the following: (a) bisphosphonates, (b) hormone replacement therapy, (c) selective-estrogen receptor modulators (SERMs), OR (d) Denosumab (Prolia).</p> <p>Osteoporosis at high risk for fracture in men (OSTm) (Initial): (1) Diagnosis of primary or hypogonadal osteoporosis (2) Both of the following: (a) Bone mineral density (BMD) T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or radius (one-third radius site) (b) One of the following (i) History of low-trauma fracture of the hip, spine, pelvis, or distal forearm (ii) inadequate response or inability to tolerate at least one osteoporosis treatment (e.g. alendronate, risedronate, zoledronic acid, Prolia [denosumab])</p>
<b>Age Restrictions</b>	(PMO, OSTm) (Initial and Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(Initial and Reauth): Remainder of contract year
<b>Other Criteria</b>	(PMO, OSTm)(Reauth): Cumulative lifetime therapy does not exceed 2 years
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# TYVASO DPI 2025

## Products Affected

- TYVASO DPI MAINTENANCE KIT INHALATION  
POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG
- TYVASO DPI TITRATION KIT INHALATION  
POWDER 16 & 32 & 48 MCG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH) (Initial): (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV. (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography. (3) Mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion. Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (Initial): (1) Diagnosis of pulmonary hypertension associated with interstitial lung disease (PHILD) WHO Group 3. (2) Diagnosis confirmed by diagnostic test(s) (e.g. right heart catheterization, doppler echocardiogram, computerized tomography imaging).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(PH-ILD)(Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Continuation): 12 months.
<b>Other Criteria</b>	(PAH)(PH-ILD)(CONTINUATION): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# UBRELVY 2025

## Products Affected

- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(AM)(Initial, Reauth): Will be used for preventative treatment of migraine. Medication will be used in combination with another oral CGRP inhibitor.
<b>Required Medical Information</b>	Acute Treatment of Migraines (AM)(Initial): (1) Diagnosis of migraine with or without aura in adults. (2) Member has fewer than 15 headache days per month. (3) inadequate response or inability to tolerate ONE generic formulary triptan.
<b>Age Restrictions</b>	(AM)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(AM)(Initial, Reauth): Prescribed by or in consultation with a neurologist or headache specialist certified by the United Council for Neurologic Subspecialties, or pain specialist.
<b>Coverage Duration</b>	(AM)(Initial): 6 months. (AM)(Reauth): 12 months
<b>Other Criteria</b>	(AM)(REAUTH): (1) Positive response to therapy (e.g. reduction in pain, photophobia, phonophobia, nausea)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# UPTRAVI 2025

## Products Affected

- UPTRAVI ORAL
- UPTRAVI TITRATION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(PAH)(Initial, Reauth): Taken in combination with a prostanoid/prostacyclin analogue (e.g. epoprostenol, iloprost, treprostinil)
<b>Required Medical Information</b>	Pulmonary Arterial Hypertension (PAH)(Initial): (1) Diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II to IV AND (2) Diagnosis confirmed by catheterization (right-heart or Swan-Ganz) or echocardiography AND (3) Documentation of mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest or greater than 30 mm Hg with exertion AND (4) inadequate response or inability to tolerate TWO of the following (a) an endothelin receptor antagonist (Tracleer if naive to the class) (b) a phosphodiesterase inhibitor (sildenafil if naive to the class) (c) riociguat (Adempas).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(PAH)(Initial): Prescribed by or in consultation with a Cardiologist or Pulmonologist
<b>Coverage Duration</b>	(Initial): 6 months. (Reauth): 12 months.
<b>Other Criteria</b>	(PAH)(REAUTH): Stabilization or improvement as evaluated by a cardiologist or pulmonologist.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VEOZAH 2025

## Products Affected

- VEOZAH

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(VMS)(Initial): (1) Diagnosis of moderate to severe vasomotor symptoms due to menopause (2) Inadequate response or inability to tolerate one of the following (a) menopausal hormone therapy (e.g. estradiol tablets) (b) non-hormonal therapy (e.g. paroxetine, venlafaxine, clonidine, etc.)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(VMS)(Initial): 6 months, (Reauth): 12 months
<b>Other Criteria</b>	(VMS)(Reauth): (1) Documentation of positive clinical response to therapy (e.g. decrease in frequency and severity of vasomotor symptoms from baseline, etc.)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# VOWST 2025

## Products Affected

- VOWST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prevention of the recurrence of Clostridioides difficile infection (PCDI): (1) Diagnosis of recurrent Clostridioides difficile infection as defined by both of the following: (a) Presence of diarrhea defined as passage of 3 or more loose bowel movements within a 24-hour period for at least 2 consecutive days (b) a positive stool test for C. difficile toxin or toxigenic C. difficile (2) Member has a history of two or more recurrent episodes of CDI within 12 months (3) Member has completed at least 10 consecutive days of one of the following antibiotic therapies 2-4 days prior to initiating Vowst: (a) oral vancomycin (b) Difucid (fidaxomicin) (4) Member has completed the recommended bowel prep (e.g. 296mL of magnesium citrate) the day before and at least 8 hours prior to initiating Vowst (5) Previous episode of CDI is under control (e.g. less than 3 unformed or loose [i.e., Bristol Stool Scale type 6-7] stools per day for at least 2 consecutive days)
<b>Age Restrictions</b>	(PCDI): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(PCDI): Prescribed by or in consultation with gastroenterologist or infectious disease specialist
<b>Coverage Duration</b>	(PCDI): 14 days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# VUITY 2025

## Products Affected

- VUITY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(Presbyopia) (Initial): (1) Diagnosis of presbyopia (2) Provider confirms valid clinical rationale, which excludes lifestyle choice, as to why patient is unable to use corrective lenses (e.g. eyeglasses or contact lenses)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(Presbyopia) (Initial) (Reauth): prescribed by or in consultation with one of the following (1) Ophthalmologist, (2) Optometrist
<b>Coverage Duration</b>	(Initial): 3 months, (Reauth): 6 months
<b>Other Criteria</b>	(Presbyopia) (Reauth): (1) Documentation of positive clinical response to therapy (e.g. improvement in near vision in low light conditions without loss of distance vision)
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# WAINUA 2025

## Products Affected

- WAINUA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(hATTR amyloidosis)(Initial): (1) Diagnosis of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with polyneuropathy (2) Member has a transthyretin (TTR) mutation (e.g., V30M) (3) One of the following: (a) Member has a baseline familial amyloidotic polyneuropathy (FAP) stage of 1 or 2 (b) member has a baseline neuropathy impairment score (NIS) greater than or equal to 10 and less than or equal to 130 (c) Member has a baseline Karnofsky Performance Status score greater than 50 percent (4) Presence of clinical signs and symptoms of the disease (e.g., neuropathy)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(hATTR amyloidosis)(Initial, Cont): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	(hATTR amyloidosis)(Initial, Cont): 12 months
<b>Other Criteria</b>	(hATTR amyloidosis)(Cont): (1) Member demonstrates positive clinical response to therapy (2) One of the following: (a) Member continues to have a baseline familial amyloidotic polyneuropathy (FAP) stage of 1 or 2 (b) member continues to have a baseline neuropathy impairment score (NIS) greater than or equal to 10 and less than or equal to 130 (c) Member continues to have a baseline Karnofsky Performance Status score greater than 50 percent
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# WILSONS DISEASE 2025

---

## Products Affected

- *trientine hcl oral capsule 500 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Wilson's disease (WD): (1) Diagnosis of Wilson's disease (i.e., hepatolenticular degeneration) (2) Inadequate response or inability to tolerate a penicillamine product (e.g. Depen, Cuprimine)
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	Indefinite
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# XDEMZY 2025

---

## Products Affected

- XDEMZY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	Diagnosis of treatment of demodex blepharitis
Age Restrictions	
Prescriber Restrictions	Prescribed by or in consultation with an ophthalmologist or optometrist
Coverage Duration	6 weeks
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

# XELJANZ 2025

## Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	(RA, PsA, UC, PJIA, AS): Concurrent therapy with any other biologic disease modifying anti-rheumatic drug (DMARD), Janus kinase (JAK) inhibitors or potent immunosuppressants (e.g. azathioprine, cyclosporine)
<b>Required Medical Information</b>	Rheumatoid arthritis (RA) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of moderate to severe RA. (2) Inadequate response or inability to tolerate one DMARD: (e.g. methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine), (3) Member had inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB) or documentation demonstrating that a trial may be inappropriate. Psoriatic Arthritis (PsA) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of PsA. (2) Inadequate response or inability to tolerate at least ONE DMARD: (e.g. Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine) (3) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. Enbrel, Humira, Adalimumab-ADB) or documentation demonstrating that a trial may be inappropriate. Ulcerative Colitis (UC) [applies to Xeljanz/Xeljanz XR tablets]: (1) Diagnosis of moderate to severe UC. (2) Inadequate response or inability to tolerate at least ONE conventional therapy (e.g. corticosteroid, aminosalicylate, azathioprine or 6-mercaptopurine) (3) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira), adalimumab-adbm) or documentation demonstrating that a trial may be inappropriate. Polyarticular Juvenile Idiopathic Arthritis (PJIA) [applies to Xeljanz tablets/oral solution]: (1) Diagnosis of PJIA. (2) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira), etanercept (Enbrel), adalimumab-adbm) OR documentation demonstrating that a trial may be inappropriate. (3) Inadequate response or inability to tolerate ONE of the following: Methotrexate, Hydroxychloroquine, Leflunomide, Azathioprine, Sulfasalazine.
<b>Age Restrictions</b>	(RA, PsA, UC, AS): Member is 18 years of age or older. (PJIA): Member is 2 years of age or older.
<b>Prescriber Restrictions</b>	(RA, PJIA, AS): Prescribed by or in consultation with a rheumatologist. (PsA): Prescribed by or in consultation with a dermatologist or rheumatologist. (UC): Prescribed by or in consultation with a gastroenterologist.

PA Criteria	Criteria Details
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Ankylosing Spondylitis (AS): (1) Diagnosis of ankylosing spondylitis. (2) Inadequate response or inability to tolerate one or more TNF inhibitors (e.g. adalimumab (Humira, adalimumab-adbm, etanercept (Enbrel)) OR documentation that a trial may be inappropriate.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XENAZINE 2025

## Products Affected

- *tetrabenazine oral tablet 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Tardive Dyskinesia (TD)(Initial): (1) Diagnosis of TD, (2) Documentation is provided of ONE of the following: (a) Persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering or discontinuation of the offending medication, or (b) Member is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Tourette's Syndrome (TS): (1) Diagnosis of TS, (2) Member has tics associated with Tourette's syndrome, (3) Inadequate response or inability to tolerate haloperidol or risperidone. Chorea- Huntington's Disease (CHD): (1) Diagnosis of chorea associated with Huntington's disease
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(TS, CHD): Prescribed by or in consultation with a neurologist or a psychiatrist. (TD)(Initial, Reauth): Prescribed by or in consultation with a neurologist or a psychiatrist.
<b>Coverage Duration</b>	(TD)(Initial): 3 months. (TD)(Reauth): Indefinite. (TS, CHD): Indefinite.
<b>Other Criteria</b>	(TD)(Reauth): Positive clinical response to therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# XERMELO 2025

## Products Affected

- XERMELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Carcinoid Syndrome Diarrhea (CSD)(Initial): (1) Diagnosis of carcinoid syndrome diarrhea, (2) Diarrhea is inadequately controlled by a stable dose of somatostatin analog (SSA) therapy (e.g. octreotide [Sandostatin, Sandostatin LAR], lanreotide [Somatuline Depot]) for at least 3 months, (3) Used in combination with SSA therapy
<b>Age Restrictions</b>	(CSD)(Initial, Reauth): Member is 18 years of age or older
<b>Prescriber Restrictions</b>	(CSD)(Initial, Reauth): Prescribed by or in consultation with an Oncologist, Endocrinologist, or Gastroenterologist
<b>Coverage Duration</b>	(Initial): 12 months (Reauth): Indefinite
<b>Other Criteria</b>	(CSD)(Reauth): (1) Positive clinical response to Xermelo therapy, (2) Xermelo will continue to be used in combination with SSA therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XGEVA 2025

## Products Affected

- XGEVA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Part D is medically necessary when: Prevention of Skeletal Related Events in Multiple Myeloma or Bone Metastases from Solid Tumors (MM-BMST) : (1) For prevention of skeletal related events in multiple myeloma or bone metastases from solid tumors. Giant Cell Tumor of the Bone (GCTB): (1) Diagnosis of GCTB. (2) Member is (a) adult or (b) adolescent that is skeletally mature. (3) Tumor is unresectable or surgical resection is likely to result in severe morbidity. Hypercalcemia of Malignancy Refractory to Bisphosphonates (HCMRB): (1) Diagnosis of HCMRB.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(GCTB, HCMRB): Prescribed by or in consultation with an urologist, oncologist or hematologist.
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Subject to Part B vs Part D review. (All Indications): Approve if for continuation of therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XIFAXAN 2025

## Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Prophylaxis for Hepatic Encephalopathy (HE): (1) Diagnosis of hepatic disease with risk for hepatic encephalopathy (i.e. previous episode of hepatic encephalopathy, advanced liver disease, hepatocellular carcinoma), (2) Inadequate response or inability to tolerate lactulose. Irritable Bowel Syndrome (IBS): (1) Diagnosis of irritable bowels syndrome- diarrhea, (2) Inadequate response or inability to tolerate BOTH of the following: (A) ONE of the following: (i) ONE Tricyclic antidepressant or (ii)selective serotonin reuptake inhibitor and (B) dicyclomine (3): BOTH of the following: (A) Member does not exceed 3 total courses (42 days in total) of therapy, (B) Member experiences irritable bowel syndrome with diarrhea (IBS-D) symptoms. Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO) (Initial): (1) Diagnosis of Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	(HE): Indefinite. (IBS): 2 weeks. (SBBO/SIBO): Initial and Reauth: 2 weeks.
<b>Other Criteria</b>	(SBBO/SIBO) (Reauth): (1) Documentation of Small Bowel Bacterial Overgrowth (SBBO)/Small Intestinal Bacterial Overgrowth (SIBO) recurrence following successful initial treatment
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XOLAIR 2025

## Products Affected

- XOLAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	Concurrent therapy with any other biologic agents for asthma/allergic conditions (e.g. benralizumab [Fasenra], dupilumab [Dupixent], mepolizumab [Nucala], omalizumab [Xolair])
<b>Required Medical Information</b>	Part D is medically necessary for: Moderate to Severe Persistent Allergic Asthma (PAA)(Initial): (1) Diagnosis of moderate to severe persistent allergic asthma, (2) The individual has a positive skin test or in vitro reactivity to a perennial aeroallergen, (3) The individual has a baseline serum IgE level of between 30 IU/mL and 1300 IU/mL, (4) Inadequate response or inability to tolerate a combination of high-dose inhaled corticosteroids (ICS) with a long-acting beta-agonist (LABA). Chronic Urticaria (CU)(Initial): (1) Diagnosis of chronic urticaria, (2) an inadequate response, contraindication or inability to tolerate ONE second-generation H1 antihistamine at the maximally tolerated dose in addition to ANY of the following: (a) leukotriene receptor antagonist (e.g. montelukast) (b) histamine H2-receptor antagonist (e.g. ranitidine, cimetidine, famotidine), (c) substituting to a different second-generation antihistamine, (d) systemic glucocorticosteroids or (e) cyclosporine, (3) will be used concurrently with an h1 antihistamine, unless there is contraindication or intolerance to H1 antihistamines. Nasal Polyps (NP)(Initial): (1) Diagnosis of nasal polyps. (2) Member will use concurrently with nasal corticosteroid. (3) Member had inadequate response or inability to tolerate an intranasal corticosteroid. (4) Member has a baseline serum IgE level of between 30 IU/mL and 1500 IU/mL
<b>Age Restrictions</b>	(PAA)(Initial, Reauth): Member is 6 years of age or older (CU)(Initial, Reauth): Member is 12 years of age and older (NP)(Initial, Reauth): Member is 18 years of age and older
<b>Prescriber Restrictions</b>	(PAA)(Initial, Reauth): Prescribed by or in consultation with an Allergist, Immunologist, or Pulmonologist. (CU)(Initial, Reauth): Prescribed by or in consultation with allergist/immunologist, dermatologist. (NP)(Initial, Reauth): Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or ENT specialist.
<b>Coverage Duration</b>	(Initial): 12 months. (Reauth): 12 months.

PA Criteria	Criteria Details
<b>Other Criteria</b>	Subject to Part B vs Part D review. (PAA)(Reauth): (1) documentation of positive clinical response to therapy (e.g. reduction in number of asthma exacerbations, improvement in forced expiratory volume in 1 second (FEV1), or decreased use of rescue medications). (CU)(Reauth): (1) Member's disease status has been re-evaluated since the last authorization to confirm the member's condition warrants continued treatment (2) member has experienced one or both of the following: (a) Reduction in itching severity from baseline (b) Reduction in number of hives from baseline. (NP)(Reauth): (1) Documentation of positive clinical response to therapy (e.g. reduction in nasal polyps score [NPS: 0-8 scale], improvement in nasal congestion/obstruction score [NCS: 0-3 scale]) (2) Used in combination with another agent for nasal polyps.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XYREM 2025

## Products Affected

- XYREM

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CN, EDSN (Initial, Reauth): Concurrent use of sedative hypnotics and alcohol
<b>Required Medical Information</b>	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy, (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Diagnosis Confirmed by Polysomnography (PSG) or Multiple sleep latency test (MSLT) or prescriber provides justification that a sleep study is not feasible and (3) Inadequate response or inability to modafinil or armodafinil. (adult use only)
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CN, EDSN)(Initial, Reauth): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# XYWAV 2025

## Products Affected

- XYWAV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	Cataplexy in Narcolepsy (CN)(Initial): (1) Diagnosis of cataplexy in narcolepsy. Excessive Daytime Sleepiness in Narcolepsy (EDSN)(Initial): (1) Diagnosis of EDSN (Narcolepsy Type 2), (2) Inadequate response or inability to modafinil. Idiopathic Hypersomnia (IH) (Initial): (1) Diagnosis of Idiopathic Hypersomnia as confirmed by sleep study (unless the prescriber provides justification confirming that a sleep study would not be feasible), (2) Symptoms of excessive daytime sleepiness (e.g. nap duration of longer than 60 minutes) are present
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	(CN, EDSN, IH)(Initial, Reauth): Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.
<b>Coverage Duration</b>	(Initial, Reauth): 12 months
<b>Other Criteria</b>	(CN, EDSN)(Reauth): (1) Documentation to support the efficacy associated with the current regimen (including but not limited to reduction in the frequency of cataplexy attacks or an improvement in the Epworth sleepiness scale), (2) Member is re-evaluated every 12 months. (IH) (Reauth): (1) Documentation demonstrating a reduction in symptoms of excessive daytime sleepiness associated with therapy.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

# ZTALMY 2025

## Products Affected

- ZTALMY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(CDKL5): (1) Diagnosis of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (2) Documentation of mutation in the CDKL5 gene (3) member is experiencing motor seizures (e.g. bilateral tonic, generalized tonic-clonic, bilateral clonic, atonic, focal, or bilateral tonic-clonic) (4) Inadequate response or inability to tolerate two formulary anticonvulsants (e.g. valproic acid, levetiracetam, lamotrigine)
<b>Age Restrictions</b>	(CDKL5): Member is 2 years of age or older
<b>Prescriber Restrictions</b>	(CDKL5): Prescribed by or in consultation with a neurologist
<b>Coverage Duration</b>	Indefinite
<b>Other Criteria</b>	Approve if for continuation of therapy
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



# ZURZUVAE 2025

## Products Affected

- ZURZUVAE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	(PPD): (1) Diagnosis of Postpartum depression (PPD) (2) Inadequate response or inability to tolerate (a) one generic Selective serotonin reuptake inhibitor (SSRI) (b) One generic Serotonin-Norepinephrine reuptake inhibitor (SNRI) (3) Medication will not be used for greater than 14 days
<b>Age Restrictions</b>	Member is 18 years of age or older
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	14 days
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No



## Index

<i>abiraterone acetate</i> .....	109	CALQUENCE ORAL TABLET .....	109
ACTEMRA ACTPEN.....	4	CAPLYTA.....	25
ACTEMRA SUBCUTANEOUS.....	4	CAPRELSA.....	109
ACTHAR.....	6	<i>carisoprodol oral</i> .....	74
<i>adalimumab-adbm (2 pen)</i> .....	10	CAYSTON.....	26
<i>adalimumab-adbm (2 syringe)</i> .....	10	<i>chlordiazepoxide-clidinium</i> .....	17
<i>adalimumab-adbm(cd/uc/hs strt)</i> .....	10	CHOLBAM.....	27
<i>adalimumab-adbm(ps/uv starter)</i> .....	10	CIBINQO.....	29
ADBRY SUBCUTANEOUS SOLUTION		CIMZIA (2 SYRINGE).....	30
PREFILLED SYRINGE.....	12	CIMZIA SUBCUTANEOUS KIT 2 X 200 MG.....	30
ADEMPAS.....	13	CLIMARA PRO.....	71
AIMOVIG.....	14	COMETRIQ (100 MG DAILY DOSE) ORAL KIT	
AKEEGA.....	109	80 & 20 MG.....	109
ALECENSA.....	109	COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3	
ALUNBRIG ORAL TABLET.....	109	X 20 MG & 80 MG.....	109
<i>ambrisentan</i> .....	15	COMETRIQ (60 MG DAILY DOSE).....	109
AMPYRA.....	16	COPIKTRA.....	109
ARIKAYCE.....	18	CORLANOR ORAL SOLUTION.....	33
<i>armodafinil</i> .....	19	CORTROPHIN.....	6
AUGTYRO.....	109	COSENTYX (300 MG DOSE).....	34
AUSTEDO.....	20	COSENTYX SENSOREADY (300 MG).....	34
AUSTEDO XR.....	20	COSENTYX SUBCUTANEOUS SOLUTION	
AUVELITY.....	21	PREFILLED SYRINGE 75 MG/0.5ML.....	34
AYVAKIT.....	109	COSENTYX UNOREADY.....	34
BALVERSA.....	109	COTELLIC.....	109
BENLYSTA SUBCUTANEOUS.....	22	CRESEMBA ORAL.....	35
BESREMI.....	23	<i>cyclobenzaprine hcl er oral capsule extended</i>	
<i>bexarotene</i> .....	109, 152	<i>release 24 hour 15 mg</i> .....	70
<i>bosentan</i> .....	154	<i>cyclobenzaprine hcl oral</i> .....	70
BOSULIF ORAL CAPSULE 50 MG.....	109	<i>dalfampridine er</i> .....	36
BOSULIF ORAL TABLET.....	109	DAURISMO.....	109
BRAFTOVI ORAL CAPSULE 75 MG.....	109	DAYVIGO.....	37
BRUKINSA.....	109	<i>deferasirox oral tablet</i> .....	38
<i>butalbital-acetaminophen oral tablet 50-325</i>		<i>deferasirox oral tablet soluble</i> .....	38
<i>mg</i> .....	69	<i>deferiprone</i> .....	61
<i>butalbital-apap-caff-cod</i> .....	69	<i>deflazacort oral tablet</i> .....	46
<i>butalbital-apap-caffeine oral capsule</i> .....	69	DIACOMIT.....	39
<i>butalbital-apap-caffeine oral tablet 50-325-</i>		<i>diclofenac epolamine external</i> .....	42
<i>40 mg</i> .....	69	<i>diclofenac sodium external gel 3 %</i> .....	41
<i>butalbital-aspirin-caffeine oral capsule</i> .....	69	<i>dipyridamole oral</i> .....	69
BYDUREON BCISE.....	96	DOPTELET ORAL TABLET 20 MG.....	43
BYETTA 10 MCG PEN SUBCUTANEOUS		DOTTI.....	71
SOLUTION PEN-INJECTOR.....	96	DUPIXENT SUBCUTANEOUS SOLUTION	
BYETTA 5 MCG PEN SUBCUTANEOUS		PREFILLED SYRINGE 200 MG/1.14ML, 300	
SOLUTION PEN-INJECTOR.....	96	MG/2ML.....	44
CABOMETYX.....	109	EMGALITY.....	47

EMGALITY (300 MG DOSE).....	47	GAMMAKED INJECTION SOLUTION 1	
EMSAM.....	49	GM/10ML.....	81
ENBREL MINI.....	50	GAMMAPLEX INTRAVENOUS SOLUTION 10	
ENBREL SUBCUTANEOUS SOLUTION 25		GM/100ML, 10 GM/200ML, 20 GM/200ML, 5	
MG/0.5ML.....	50	GM/50ML.....	81
ENBREL SUBCUTANEOUS SOLUTION		GAMUNEX-C INJECTION SOLUTION 1	
PREFILLED SYRINGE.....	50	GM/10ML.....	81
ENBREL SURECLICK SUBCUTANEOUS		GAVRETO.....	109
SOLUTION AUTO-INJECTOR.....	50	<i>gefitinib</i> .....	109
ENDARI.....	51	GENOTROPIN SUBCUTANEOUS CARTRIDGE.....	65
EPCLUSA.....	122	GILOTRIF.....	109
EPIDIOLEX.....	52	GLEOSTINE ORAL CAPSULE 10 MG, 100 MG,	
ERIVEDGE.....	109	40 MG.....	109
ERLEADA.....	109	GOCOVRI.....	64
<i>erlotinib hcl</i> .....	109	HAEGARDA.....	67
ESBRIET.....	53	HARVONI ORAL PACKET.....	122
<i>estradiol transdermal patch twice weekly</i> .....	71	HARVONI ORAL TABLET 90-400 MG.....	122
<i>estradiol transdermal patch weekly 0.025</i>		HUMATROPE INJECTION CARTRIDGE.....	65
<i>mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr,</i>		HUMIRA (2 SYRINGE) SUBCUTANEOUS	
<i>0.06 mg/24hr, 0.075 mg/24hr</i> .....	71	PREFILLED SYRINGE KIT 10 MG/0.1ML, 20	
<i>eszopiclone oral tablet 3 mg</i> .....	73	MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML.....	10
EUCRISA.....	54	<i>hydrocodone bitartrate er oral capsule</i>	
EVENITY.....	55	<i>extended release 12 hour 10 mg, 15 mg</i> .....	3
<i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5</i>		<i>hydromorphone hcl er oral tablet extended</i>	
<i>mg</i> .....	109	<i>release 24 hour 12 mg, 8 mg</i> .....	68
<i>everolimus oral tablet soluble</i> .....	109	<i>hydromorphone hcl oral tablet 4 mg, 8 mg</i> .....	68
EYSUVIS.....	57	IBRANCE.....	109
FASENRA.....	58	ICLUSIG.....	109
FASENRA PEN.....	58	IDHIFA.....	109
<i>fentanyl citrate buccal lozenge on a handle</i> .....	60	ILUMYA.....	75
<i>fentanyl transdermal patch 72 hour 100</i>		<i>imatinib mesylate</i> .....	109
<i>mcg/hr, 25 mcg/hr, 37.5 mcg/hr</i> .....	68	IMBRUVICA ORAL CAPSULE.....	109
<i>fentanyl transdermal patch 72 hour 50 mcg/hr,</i>		IMBRUVICA ORAL SUSPENSION.....	109
<i>75 mcg/hr</i> .....	68	IMBRUVICA ORAL TABLET 140 MG, 280 MG,	
FERRIPROX ORAL TABLET 1000 MG.....	61	420 MG.....	109
FERRIPROX TWICE-A-DAY.....	61	INBRIJA.....	76
FINTEPLA.....	62	INCRELEX.....	77
FIRAZYR SUBCUTANEOUS SOLUTION		INGREZZA.....	78
PREFILLED SYRINGE.....	8	INLYTA.....	109
FORTEO SUBCUTANEOUS SOLUTION PEN-		INQOVI.....	109
INJECTOR 600 MCG/2.4ML.....	148	INREBIC.....	109
FOTIVDA.....	109	INTRAROSA.....	117
FRUZAQLA.....	109	<i>ivabradine hcl</i> .....	33
GALAFOLD.....	63	IWILFIN.....	109
GAMMAGARD INJECTION SOLUTION 2.5		JAKAFI.....	109
GM/25ML.....	81	JATENZO.....	150
GAMMAGARD S/D LESS IGA.....	81	JAYPIRCA.....	109

JINTELI .....	71	<i>morphine sulfate er oral capsule extended</i>	
JUBLIA .....	107	<i>release 24 hour 80 mg.....</i>	68
KALYDECO .....	83	<i>morphine sulfate er oral tablet extended release</i>	
KERENDIA .....	84	<i>100 mg, 60 mg.....</i>	68
<i>ketorolac tromethamine oral.....</i>	72	<i>naproxen-esomeprazole mg oral tablet delayed</i>	
KEVZARA .....	85	<i>release 500-20 mg.....</i>	32
KINERET SUBCUTANEOUS SOLUTION		NAYZILAM .....	9
PREFILLED SYRINGE .....	86	NERLYNX .....	109
KISQALI (200 MG DOSE) .....	109	NEXLETOL .....	93
KISQALI (400 MG DOSE) .....	109	NEXLIZET .....	93
KISQALI (600 MG DOSE) .....	109	NINLARO .....	109
KOSELUGO .....	109	NORDITROPIN FLEXPPO SUBCUTANEOUS	
KRAZATI .....	109	SOLUTION PEN-INJECTOR.....	65
<i>lapatinib ditosylate.....</i>	109	NOURIANZ .....	97
<i>lenalidomide.....</i>	109	NUBEQA .....	109
LENVIMA (10 MG DAILY DOSE) .....	109	NUCALA .....	99
LENVIMA (12 MG DAILY DOSE) .....	109	NUDEXTA .....	101
LENVIMA (14 MG DAILY DOSE) .....	109	NUPLAZID ORAL CAPSULE .....	102
LENVIMA (18 MG DAILY DOSE) .....	109	NUPLAZID ORAL TABLET 10 MG.....	102
LENVIMA (20 MG DAILY DOSE) .....	109	NURTEC.....	103
LENVIMA (24 MG DAILY DOSE) .....	109	NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS	
LENVIMA (4 MG DAILY DOSE) .....	109	SOLUTION PEN-INJECTOR.....	65
LENVIMA (8 MG DAILY DOSE) .....	109	NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS	
LETAIRIS .....	88	SOLUTION PEN-INJECTOR.....	65
<i>l-glutamine oral packet.....</i>	51	NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS	
LIBERVANT .....	9	SOLUTION PEN-INJECTOR.....	65
<i>lidocaine external patch 5 %.....</i>	89	OCALIVA .....	104
LIDOCAN .....	89	OCTAGAM INTRAVENOUS SOLUTION 1	
LIVTENCITY .....	90	GM/20ML, 2 GM/20ML.....	81
LONSURF .....	109	ODOMZO .....	109
LORBRENA .....	109	OFEV .....	105
LUMAKRAS .....	109	OGSIVEO .....	109
LYBALVI.....	24	OJEMDA ORAL SUSPENSION RECONSTITUTED	
LYNPARZA ORAL TABLET .....	109	.....	109
LYTGOBI (12 MG DAILY DOSE) .....	109	OJEMDA ORAL TABLET 100 MG.....	109
LYTGOBI (16 MG DAILY DOSE) .....	109	OJJAARA .....	109
LYTGOBI (20 MG DAILY DOSE) .....	109	OLUMIANT .....	106
MAVYRET .....	122	OMNITROPE SUBCUTANEOUS SOLUTION	
MEKINIST .....	109	CARTRIDGE 5 MG/1.5ML.....	65
MEKTOVI.....	109	ONUREG .....	109
MENOSTAR.....	71	OPSUMIT .....	112
<i>metaxalone.....</i>	69	OPZELURA .....	108
<i>metformin hcl er (mod).....</i>	56	ORENCIA CLICKJECT.....	113
<i>methadone hcl oral tablet.....</i>	68	ORENCIA SUBCUTANEOUS SOLUTION	
<i>mifepristone oral tablet 300 mg.....</i>	87	PREFILLED SYRINGE.....	113
<i>modafinil oral.....</i>	91	ORGOVYX.....	109
		ORKAMBI.....	114

ORMALVI .....	40	REPATHA SURECLICK .....	129
ORSERDU .....	109	RETEVMO .....	109
OSPHENA .....	117	REVLIMID .....	109
OTEZLA .....	115	REZLIDHIA .....	109
OTREXUP SUBCUTANEOUS SOLUTION		REZUROCK .....	132
AUTO-INJECTOR 10 MG/0.4ML, 12.5		RINVOQ .....	133
MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20		ROZLYTREK .....	109
MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML .....	80	RUBRACA .....	109
OXERVATE .....	116	RYBELSUS .....	121
<i>oxycodone hcl oral tablet 30 mg</i> .....	68	RYDAPT .....	109
<i>oxymorphone hcl er oral tablet extended release</i>		SCEMBLIX .....	109
<i>12 hour 30 mg</i> .....	68	SIGNIFOR .....	135
OZEMPIC (0.25 OR 0.5 MG/DOSE)		<i>sildenafil citrate oral suspension reconstituted</i> .....	136
SUBCUTANEOUS SOLUTION PEN-INJECTOR 2		<i>sildenafil citrate oral tablet 20 mg</i> .....	136
MG/3ML .....	121	SIMPONI SUBCUTANEOUS SOLUTION AUTO-	
OZEMPIC (1 MG/DOSE) SUBCUTANEOUS		INJECTOR .....	137
SOLUTION PEN-INJECTOR 4 MG/3ML .....	121	SIMPONI SUBCUTANEOUS SOLUTION	
OZEMPIC (2 MG/DOSE) .....	121	PREFILLED SYRINGE .....	137
<i>pazopanib hcl</i> .....	109	SIRTURO .....	139
PEMAZYRE .....	109	SKYRIZI PEN .....	140
PIQRAY (200 MG DAILY DOSE) .....	109	SKYRIZI SUBCUTANEOUS .....	140
PIQRAY (250 MG DAILY DOSE) .....	109	<i>sofosbuvir-velpatasvir</i> .....	122
PIQRAY (300 MG DAILY DOSE) .....	109	<i>sorafenib tosylate</i> .....	109
<i>pirfenidone</i> .....	53	SPRYCEL .....	109
POMALYST .....	109	STELARA SUBCUTANEOUS SOLUTION 45	
<i>posaconazole oral tablet delayed release</i> .....	98	MG/0.5ML .....	141
PRALUENT SUBCUTANEOUS SOLUTION		STELARA SUBCUTANEOUS SOLUTION	
AUTO-INJECTOR .....	119	PREFILLED SYRINGE .....	141
PREMARIN ORAL .....	71	STIVARGA .....	109
PRIVIGEN INTRAVENOUS SOLUTION 20		<i>sunitinib malate</i> .....	109
GM/200ML .....	81	SUTENT .....	109
PROLASTIN-C INTRAVENOUS SOLUTION .....	131	TABRECTA .....	109
PROLIA SUBCUTANEOUS SOLUTION		<i>tadalafil (pah)</i> .....	118
PREFILLED SYRINGE .....	123	<i>tadalafil oral tablet 2.5 mg, 5 mg</i> .....	28
PROMACTA .....	125	TAFINLAR .....	109
<i>promethazine hcl oral solution</i> .....	69	TAGRISSO .....	109
<i>promethazine hcl oral tablet 12.5 mg, 25 mg</i> .....	17	TALTZ .....	143
QINLOCK .....	109	TALZENNA .....	109
<i>quinine sulfate oral</i> .....	127	TASIGNA .....	109
RADICAVA ORS STARTER KIT .....	128	<i>tavorole</i> .....	107
RASUVO SUBCUTANEOUS SOLUTION AUTO-		TAVNEOS .....	145
INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15		TAZVERIK .....	109
MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML,		TEGSEDI .....	146
22.5 MG/0.45ML, 25 MG/0.5ML, 30		TEPMETKO .....	109
MG/0.6ML, 7.5 MG/0.15ML .....	80	<i>teriparatide subcutaneous solution pen-injector</i>	
REPATHA .....	129	<i>620 mcg/2.48ml</i> .....	148
REPATHA PUSHTRONEX SYSTEM .....	129		

<i>testosterone cypionate intramuscular solution</i>	VOWST .....	161
100 mg/ml, 200 mg/ml.....	VUITY .....	162
<i>testosterone enanthate intramuscular solution</i>	VYNDAMAX .....	142
150	VYNDAQEL .....	142
<i>testosterone transdermal gel 10 mg/act (2%),</i>	WAINUA .....	163
<i>12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%),</i>	WELIREG .....	109
<i>20.25 mg/act (1.62%), 25 mg/2.5gm (1%),</i>	XALKORI .....	109
<i>40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%).</i>	XDEMVY .....	165
150	XELJANZ .....	166
<i>testosterone transdermal solution</i> .....	XELJANZ XR .....	166
150	XERMELO .....	169
<i>tetrabenazine oral tablet 25 mg</i> .....	XGEVA .....	170
168	XIFAXAN ORAL TABLET 550 MG .....	171
THALOMID ORAL CAPSULE 100 MG, 50 MG ...	XOLAIR .....	172
109	XOSPATA .....	109
TIBSOVO .....	XPOVIO (100 MG ONCE WEEKLY) ORAL	
109	TABLET THERAPY PACK 50 MG .....	109
TOBI PODHALER .....	XPOVIO (40 MG ONCE WEEKLY) ORAL	
79	TABLET THERAPY PACK 40 MG .....	109
TRACLEER .....	XPOVIO (40 MG TWICE WEEKLY) ORAL	
154	TABLET THERAPY PACK 40 MG .....	109
TRELSTAR MIXJECT .....	XPOVIO (60 MG ONCE WEEKLY) ORAL	
95	TABLET THERAPY PACK 60 MG .....	109
TREMFYA SUBCUTANEOUS SOLUTION	XPOVIO (60 MG TWICE WEEKLY) .....	109
PREFILLED SYRINGE 100 MG/ML .....	XPOVIO (80 MG ONCE WEEKLY) ORAL	
155	TABLET THERAPY PACK 40 MG .....	109
<i>tretinoin external</i> .....	XPOVIO (80 MG TWICE WEEKLY) .....	109
153	XTAMPZA ER .....	3, 68
TRIDACAINE II .....	XTANDI .....	109
89	XYOSTED .....	150
<i>trientine hcl oral capsule 500 mg</i> .....	XYREM .....	174
164	XYWAV .....	175
TRUQAP .....	ZEJULA ORAL TABLET .....	109
109	ZELBORAF .....	109
TUKYSA .....	ZOLINZA .....	109
109	<i>zolpidem tartrate er oral tablet extended</i>	
TURALIO ORAL CAPSULE 125 MG .....	<i>release 12.5 mg</i> .....	73
109	<i>zolpidem tartrate oral tablet 10 mg</i> .....	73
TYMLOS .....	ZTALMY .....	176
156	ZURZUVAE .....	177
TYVASO DPI MAINTENANCE KIT INHALATION	ZYDELIG .....	109
POWDER 16 MCG, 32 MCG, 48 MCG, 64 MCG	ZYKADIA ORAL TABLET .....	109
157	ZYTIGA .....	109
TYVASO DPI TITRATION KIT INHALATION		
POWDER 16 & 32 & 48 MCG .....		
157		
UBRELVY .....		
158		
UPTRAVI ORAL .....		
159		
UPTRAVI TITRATION .....		
159		
VALCHLOR .....		
152		
VALTOCO 10 MG DOSE .....		
9		
VALTOCO 15 MG DOSE .....		
9		
VALTOCO 20 MG DOSE .....		
9		
VALTOCO 5 MG DOSE .....		
9		
VANFLYTA .....		
109		
VENCLEXTA .....		
109		
VENCLEXTA STARTING PACK .....		
109		
VEOZAH .....		
160		
VERZENIO .....		
109		
VICTOZA SUBCUTANEOUS SOLUTION PEN-		
INJECTOR .....		
121		
VITRAKVI .....		
109		
VIZIMPRO .....		
109		
VONJO .....		
109		
<i>voriconazole intravenous</i> .....		
117		
VOTRIENT .....		
109		